10-Q

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number: 001-13149

STRYKER CORPORATION
(Exact name of registrant as specified in its charter)

Michigan			38-1239739
(State of incorporation)			(I.R.S. Employer Identification No.)
2825 Airview Boulevard	Kalamazoo,	Michigan	49002
(Address of principal executive offices)			(Zip Code)
	(269)	385-2600
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.10 Par Value	SYK	New York Stock Exchange
1.125% Notes due 2023	SYK23	New York Stock Exchange
0.250% Notes due 2024	SYK24A	New York Stock Exchange
2.125% Notes due 2027	SYK27	New York Stock Exchange
0.750% Notes due 2029	SYK29	New York Stock Exchange
2.625% Notes due 2030	SYK30	New York Stock Exchange
1.000% Notes due 2031	SYK31	New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒    No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒    No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐	Emerging growth company	☐
Non-accelerated filer	☐	Small reporting company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐    No ☒

There were 378,154,080 shares of Common Stock, $0.10 par value, on March 31, 2022.

STRYKER CORPORATION 2022 First Quarter Form 10-Q

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

Stryker Corporation and Subsidiaries

CONSOLIDATED STATEMENTS OF EARNINGS (Unaudited)

	Three Months
	2022		2021
Net sales	$	4,275	$	3,953
Cost of sales	1,541		1,444
Gross profit	$	2,734	$	2,509
Research, development and engineering expenses	413		288
Selling, general and administrative expenses	1,710		1,575
Recall charges	14		6
Amortization of intangible assets	150		181
Total operating expenses	$	2,287	$	2,050
Operating income	$	447	$	459
Other income (expense), net	(61)		(92)
Earnings before income taxes	$	386	$	367
Income taxes	63		65
Net earnings	$	323	$	302
Net earnings per share of common stock:
Basic	$	0.86	$	0.80
Diluted	$	0.84	$	0.79
Weighted-average shares outstanding (in millions):
Basic	377.7		376.3
Effect of dilutive employee stock compensation	5.0		5.4
Diluted	382.7		381.7
Cash dividends declared per share of common stock	$	0.695	$	0.63

Anti-dilutive shares excluded from the calculation of dilutive employee stock options were de minimis in all periods.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Unaudited)

	Three Months
	2022		2021
Net earnings	$	323	$	302
Other comprehensive income (loss), net of tax:
Marketable securities	(1)		—
Pension plans	(1)		7
Unrealized gains (losses) on designated hedges	1		28
Financial statement translation	53		255
Total other comprehensive income (loss), net of tax	$	52	$	290
Comprehensive income	$	375	$	592

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 1

STRYKER CORPORATION 2022 First Quarter Form 10-Q

CONSOLIDATED BALANCE SHEETS

	March 31		December 31
	2022		2021
	(Unaudited)
Assets
Current assets
Cash and cash equivalents	$	1,458	$	2,944
Marketable securities	72		75
Accounts receivable, less allowance of $140 ($167 in 2021)	2,991		3,022
Inventories:
Materials and supplies	750		691
Work in process	298		264
Finished goods	2,477		2,359
Total inventories	$	3,525	$	3,314
Prepaid expenses and other current assets	679		662
Total current assets	$	8,725	$	10,017
Property, plant and equipment:
Land, buildings and improvements	1,708		1,656
Machinery and equipment	3,824		3,842
Total property, plant and equipment	$	5,532	$	5,498
Less accumulated depreciation	2,739		2,665
Property, plant and equipment, net	$	2,793	$	2,833
Goodwill	15,228		12,918
Other intangibles, net	5,430		4,840
Noncurrent deferred income tax assets	1,602		1,760
Other noncurrent assets	2,359		2,263
Total assets	$	36,137	$	34,631
Liabilities and shareholders' equity
Current liabilities
Accounts payable	$	1,084	$	1,129
Accrued compensation	703		1,092
Income taxes	173		192
Dividends payable	263		263
Accrued product liabilities	430		401
Accrued expenses and other liabilities	1,541		1,465
Current maturities of debt	214		7
Total current liabilities	$	4,408	$	4,549
Long-term debt, excluding current maturities	13,885		12,472
Income taxes	917		913
Other noncurrent liabilities	1,881		1,820
Total liabilities	$	21,091	$	19,754
Shareholders' equity
Common stock, $0.10 par value	38		38
Additional paid-in capital	1,947		1,890
Retained earnings	13,540		13,480
Accumulated other comprehensive loss	(479)		(531)
Total shareholders' equity	$	15,046	$	14,877
Total liabilities and shareholders' equity	$	36,137	$	34,631

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 2

STRYKER CORPORATION 2022 First Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited)

	Three Months
	2022		2021
Common stock shares outstanding (in millions)
Beginning	377.5		376.1
Issuance of common stock under stock compensation and benefit plans	0.7		0.6
Ending	378.2		376.7
Common stock
Beginning	$	38	$	38
Issuance of common stock under stock compensation and benefit plans	—		—
Ending	$	38	$	38
Additional paid-in capital
Beginning	$	1,890	$	1,741
Issuance of common stock under stock compensation and benefit plans	(14)		(3)
Share-based compensation	71		68
Ending	$	1,947	$	1,806
Retained earnings
Beginning	$	13,480	$	12,462
Net earnings	323		302
Cash dividends declared	(263)		(239)
Ending	$	13,540	$	12,525
Accumulated other comprehensive income (loss)
Beginning	$	(531)	$	(1,157)
Other comprehensive income (loss)	52		290
Ending	$	(479)	$	(867)
Total shareholders' equity	$	15,046	$	13,502

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 3

STRYKER CORPORATION 2022 First Quarter Form 10-Q

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)

	Three Months
	2022		2021
Operating activities
Net earnings	$	323	$	302
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	92		95
Amortization of intangible assets	150		181
Share-based compensation	71		68
Recall charges	14		6
Sale of inventory stepped-up to fair value at acquisition	5		79
Changes in operating assets and liabilities:
Accounts receivable	53		65
Inventories	(229)		(73)
Accounts payable	(52)		(37)
Accrued expenses and other liabilities	(348)		(178)
Recall-related payments	(9)		(8)
Income taxes	(3)		6
Other, net	136		(54)
Net cash provided by operating activities	$	203	$	452
Investing activities
Acquisitions, net of cash acquired	(2,563)		(27)
Purchases of marketable securities	(9)		(5)
Proceeds from sales of marketable securities	11		12
Purchases of property, plant and equipment	(119)		(83)
Other investing, net	(2)		7
Net cash used in investing activities	$	(2,682)	$	(96)
Financing activities
Proceeds (payments) on short-term borrowings, net	(170)		2
Proceeds from issuance of long-term debt	1,500		5
Payments on long-term debt	—		(750)
Payments of dividends	(262)		(238)
Cash paid for taxes from withheld shares	(72)		(53)
Other financing, net	(3)		(19)
Net cash provided by (used in) financing activities	$	993	$	(1,053)
Effect of exchange rate changes on cash and cash equivalents	—		(8)
Change in cash and cash equivalents	$	(1,486)	$	(705)
Cash and cash equivalents at beginning of period	2,944		2,943
Cash and cash equivalents at end of period	$	1,458	$	2,238

See accompanying notes to Consolidated Financial Statements.

Dollar amounts are in millions except per share amounts or as otherwise specified. 4

STRYKER CORPORATION 2022 First Quarter Form 10-Q

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

NOTE 1 - BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," "us" or "our") on March 31, 2022 and the results of operations for the three months 2022. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2021.

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

New Accounting Pronouncements Recently Adopted

On January 1, 2022 we adopted ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

NOTE 2 - REVENUE RECOGNITION

Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2021.

We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.

Net Sales by Product Line
	Three Months
	2022		2021
MedSurg and Neurotechnology:
Instruments	$	528	$	469
Endoscopy	538		469
Medical	664		622
Neurovascular	301		289
Neuro Cranial	323		281
Other	69		61
	$	2,423	$	2,191
Orthopaedics and Spine:
Knees	$	464	$	412
Hips	327		309
Trauma and Extremities	685		640
Spine	279		278
Other	97		123
	$	1,852	$	1,762
Total	$	4,275	$	3,953

Net Sales by Geography
	Three Months 2022				Three Months 2021
	United States		International		United States		International
MedSurg and Neurotechnology:
Instruments	$	414	$	114	$	355	$	114
Endoscopy	418		120		354		115
Medical	525		139		473		149
Neurovascular	110		191		111		178
Neuro Cranial	264		59		224		57
Other	68		1		60		1
	$	1,799	$	624	$	1,577	$	614
Orthopaedics and Spine:
Knees	$	345	$	119	$	294	$	118
Hips	202		125		186		123
Trauma and Extremities	487		198		440		200
Spine	200		79		193		85
Other	72		25		94		29
	$	1,306	$	546	$	1,207	$	555
Total	$	3,105	$	1,170	$	2,784	$	1,169

Contract Assets and Liabilities

On March 31, 2022 and December 31, 2021 contract assets recorded in our Consolidated Balance Sheets were not significant.

Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $635 and $529 on March 31, 2022 and December 31, 2021.

NOTE 3 - ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)

Three Months 2022	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	—	$	(155)	$	40	$	(416)	$	(531)
OCI	(1)		(4)		4		86		85
Income taxes	—		2		(2)		(25)		(25)
Reclassifications to:
Other (income) expense	—		2		(1)		(11)		(10)
Income taxes	—		(1)		—		3		2
Net OCI	$	(1)	$	(1)	$	1	$	53	$	52
Ending	$	(1)	$	(156)	$	41	$	(363)	$	(479)

Three Months 2021	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(259)	$	(10)	$	(885)	$	(1,157)
OCI	—		8		27		273		308
Income taxes	—		(4)		(8)		(12)		(24)
Reclassifications to:
Cost of sales	—		—		1		—		1
Other (income) expense	—		4		10		(8)		6
Income taxes	—		(1)		(2)		2		(1)
Net OCI	$	—	$	7	$	28	$	255	$	290
Ending	$	(3)	$	(252)	$	18	$	(630)	$	(867)

NOTE 4 - DERIVATIVE INSTRUMENTS

We use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency

Dollar amounts are in millions except per share amounts or as otherwise specified. 5

STRYKER CORPORATION 2022 First Quarter Form 10-Q

exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2021.

Foreign Currency Hedges

March 2022	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	711	$	2,224	$	3,993	$	6,928
Maximum term in years							4.6
Fair value:
Other current assets	$	16	$	49	$	33	$	98
Other noncurrent assets	1		74		—		75
Other current liabilities	(7)		—		(29)		(36)
Other noncurrent liabilities	(1)		—		—		(1)
Total fair value	$	9	$	123	$	4	$	136

December 2021	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	973	$	2,266	$	5,512	$	8,751
Maximum term in years							4.9
Fair value:
Other current assets	$	15	$	39	$	92	$	146
Other noncurrent assets	1		65		—		66
Other current liabilities	(7)		—		(10)		(17)
Total fair value	$	9	$	104	$	82	$	195

We had €2.0 billion at March 31, 2022 and December 31, 2021 in certain foreign currency forward contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at March 31, 2022 and December 31, 2021 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.

On March 31, 2022 the total after tax gain (loss) in AOCI related to designated net investment hedges was $42.

Net Currency Exchange Rate Gains (Losses)

Derivative		Three Months
instrument:	Recorded in:	2022		2021
Cash Flow	Cost of sales	$	—	$	(1)
Net Investment	Other income (expense), net	11		8
Non-Designated	Other income (expense), net	1		(2)
	Total	$	12	$	5

Pretax gains (losses) on derivatives designated as cash flow hedges of $13 and net investment hedges of $34 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of March 31, 2022. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the

component related to the spot-forward difference from the effectiveness assessment.

Interest Rate Hedges

Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of March 31, 2022. The cash flow effect of interest rate hedges is recorded in cash flow from operations.

NOTE 5 - FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2021.

There were no significant transfers into or out of any level of the fair value hierarchy in 2022.

Assets Measured at Fair Value	March		December
	2022		2021
Cash and cash equivalents	$	1,458	$	2,944
Trading marketable securities	182		193
Level 1 - Assets	$	1,640	$	3,137
Available-for-sale marketable securities:
Corporate and asset-backed debt securities	$	49	$	48
Foreign government debt securities	2		2
United States agency debt securities	5		5
United States Treasury debt securities	14		19
Certificates of deposit	2		1
Total available-for-sale marketable securities	$	72	$	75
Foreign currency exchange forward contracts	173		212
Level 2 - Assets	$	245	$	287
Total assets measured at fair value	$	1,885	$	3,424

Liabilities Measured at Fair Value	March		December
	2022		2021
Deferred compensation arrangements	$	182	$	193
Level 1 - Liabilities	$	182	$	193
Foreign currency exchange forward contracts	$	37	$	17
Level 2 - Liabilities	$	37	$	17
Contingent consideration:
Beginning	$	306	$	393
Additions	—		62
Change in estimate	(17)		(1)
Settlements	(4)		(148)
Ending	$	285	$	306
Level 3 - Liabilities	$	285	$	306
Total liabilities measured at fair value	$	504	$	516

Fair Value of Available for Sale Securities by Maturity
	March 2022		December 2021
Due in one year or less	$	40	$	36
Due after one year through three years	$	32	$	39

On March 31, 2022 and December 31, 2021 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income was $15 and $17 in the three months 2022 and 2021, which was recorded in other income (expense), net.

Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.

NOTE 6 - CONTINGENCIES AND COMMITMENTS

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully

Dollar amounts are in millions except per share amounts or as otherwise specified. 6

STRYKER CORPORATION 2022 First Quarter Form 10-Q

described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

In April 2022 the United States District Court for the District of Delaware issued a judgment following a jury verdict in favor of PureWick Corporation (PureWick) for its 2019 complaint seeking patent infringement damages related to our PrimaFit and PrimoFit products. The court awarded damages and we recorded charges of $28 in March 2022. If PureWick seeks enhancement of the judgment and is successful, the judgment could total approximately $100 and include an injunction against future sales. We intend to appeal the outcome of this case.

Recall Matters

In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against.

In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. In April 2022 we executed a second agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential.

With the acquisition of Wright Medical Group N.V. (Wright) in November 2020, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business. We will continue to evaluate each claim and the possible loss we may incur.

We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. For the three months 2022 we have recorded charges of $14 and made payments of $9, primarily related to Wright hip products. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.

Leases	March			December
	2022			2021
Right-of-use assets	$	490		$	419
Lease liabilities, current	$	129		$	112
Lease liabilities, non-current	$	370		$	310
Other information:
Weighted-average remaining lease term	5.5 years			5.4 years
Weighted-average discount rate	2.65		%	2.86		%

	Three Months
	2022		2021
Operating lease cost	$	31	$	36

NOTE 7 - ACQUISITIONS

We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $2,563 and $31 in the three months 2022 and 2021.

In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. This goodwill is not deductible for tax purposes.

In the three months 2022 note holders elected to redeem the 1.50% and 0.50% convertible notes assumed in the Vocera acquisition for $101 and $324. These repayments are classified as financing activities in the Consolidated Statements of Cash Flows.

Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded in selling, general and administrative expenses.

Dollar amounts are in millions except per share amounts or as otherwise specified. 7

STRYKER CORPORATION 2022 First Quarter Form 10-Q

Purchase price allocations for our significant acquisitions are:

Purchase Price Allocation of Acquired Net Assets
2022	Vocera
Tangible assets and liabilities:
Accounts receivable	$	33
Inventory	13
Deferred income tax assets	70
Other assets	92
Debt	(425)
Deferred income tax liabilities	(183)
Other liabilities	(115)
Intangible assets:
Customer and distributor relationships	550
Developed technology and patents	178
Trade name	18
Goodwill	2,332
Purchase price, net of cash acquired of $281	$	2,563
Weighted-average life of intangible assets	13

Purchase price allocations for Vocera were based on preliminary valuations, primarily related to intangible assets and deferred income taxes. Our estimates and assumptions are subject to change within the measurement period.

Consolidated Estimated Amortization Expense
Remainder of 2022		2023		2024		2025		2026
$	484	$	624	$	594	$	573	$	515

NOTE 8 - DEBT AND CREDIT FACILITIES

We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on March 31, 2022.

In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%.

In the first quarter of 2022 our Board of Directors approved an increase to the maximum amount of commercial paper that can be outstanding from $1,500 to $2,250.

On March 31, 2022 we had $195 outstanding under our commercial paper programs which allows for maturities up to 397 days from the date of issuance.

Summary of Total Debt			March 2022		December 2021
	Rate	Due
Senior unsecured notes:
	1.125%	November 30, 2023	$	610	$	622
	0.600%	December 1, 2023	594		598
	3.375%	May 15, 2024	598		593
	0.250%	December 3, 2024	941		958
	1.150%	June 15, 2025	646		645
	3.375%	November 1, 2025	748		748
	3.500%	March 15, 2026	994		994
	2.125%	November 30, 2027	829		845
	3.650%	March 7, 2028	597		597
	0.750%	March 1, 2029	885		901
	1.950%	June 15, 2030	990		990
	2.625%	November 30, 2030	714		727
	1.000%	December 3, 2031	824		840
	4.100%	April 1, 2043	392		392
	4.375%	May 15, 2044	395		395
	4.625%	March 15, 2046	982		982
	2.900%	June 15, 2050	642		642
Term loan		February 22, 2025	1,500		—
Commercial paper			195		—
Other			23		10
Total debt			$	14,099	$	12,479
Less current maturities of debt			214		7
Total long-term debt			$	13,885	$	12,472
			March 2022		December 2021
Unamortized debt issuance costs			$	59	$	62
Borrowing capacity on existing facilities			$	2,162	$	2,162
Fair value of senior unsecured notes			$	12,369	$	13,391

The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.

NOTE 9 - INCOME TAXES

Our effective tax rates were 16.3% and 17.7% in the three months 2022 and 2021. The change in the effective income tax rate for the three months was primarily due to lower tax expense from our operating structure and current profit mix.

We are routinely audited by income tax authorities in the jurisdictions we operate. It is reasonably possible within the next 12 months that uncertain tax positions, excluding interest, could decrease by as much as $175 as a result of the resolution of tax matters.

Dollar amounts are in millions except per share amounts or as otherwise specified. 8

STRYKER CORPORATION 2022 First Quarter Form 10-Q

NOTE 10 - SEGMENT INFORMATION

As previously disclosed, effective December 31, 2021 we changed our reportable business segments to (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine to align to our new internal reporting structure.

	Three Months
	2022		2021
MedSurg and Neurotechnology	$	2,423	$	2,191
Orthopaedics and Spine	1,852		1,762
Net sales	$	4,275	$	3,953
MedSurg and Neurotechnology	$	611	$	635
Orthopaedics and Spine	522		455
Segment operating income	$	1,133	$	1,090
Items not allocated to segments:
Corporate and other	$	(199)	$	(162)
Acquisition and integration-related costs	(149)		(249)
Amortization of intangible assets	(150)		(181)
Restructuring-related and other charges	(109)		(14)
Medical device regulations	(28)		(19)
Recall-related matters	(14)		(6)
Regulatory and legal matters	(37)		—
Consolidated operating income	$	447	$	459

There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2021, other than the addition of the assets acquired in the Vocera acquisition which are included in the MedSurg and Neurotechnology segment.

Dollar amounts are in millions except per share amounts or as otherwise specified. 9

STRYKER CORPORATION 2022 First Quarter Form 10-Q

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

ABOUT STRYKER

Stryker is one of the world's leading medical technology companies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in Medical and Surgical, Neurotechnology, Orthopaedics and Spine that help improve patient and hospital outcomes.

We segregate our operations into two reportable business segments: (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine. MedSurg and Neurotechnology products include surgical equipment and navigation systems (Instruments), endoscopic and communications systems (Endoscopy), patient handling, emergency medical equipment and intensive care disposable products (Medical), minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke (Neurovascular), a comprehensive line of products for traditional brain and open skull based surgical procedures; orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products (Neuro Cranial) and other medical device products used in a variety of medical specialties. Orthopaedics and Spine products consist primarily of implants used in hip and knee joint replacements and trauma and extremity surgeries, and cervical, thoracolumbar and interbody systems used in spinal injury, deformity and degenerative therapies.

COVID-19 Pandemic

The COVID-19 global pandemic has led to severe disruptions in the market and the global and United States economies that may continue for a prolonged duration and trigger a recession or a period of economic slowdown. In response, various governmental authorities and private enterprises have implemented numerous measures to contain the pandemic, such as travel bans and restrictions, quarantines, shelter-in-place orders and shutdowns. A significant number of our global suppliers, vendors, distributors and manufacturing facilities are located in regions that have been affected by the pandemic. Those operations have been materially adversely affected by restrictive government and private enterprise measures implemented in response to the pandemic.

Some of our products are particularly sensitive to reductions in elective medical procedures. During the quarter we saw a partial recovery of elective procedures and accelerated sales momentum as the impact of the COVID-19 pandemic has eased in the United States and Europe; however, our sales growth in certain of our products has been constrained by the continuing supply chain challenges and electronic component shortages, especially impacting the capital products in our MedSurg businesses.

Russia and Ukraine Conflict

The military conflict in Russia and Ukraine and the sanctions imposed by the United States government and other nations in response to this conflict have caused significant volatility and disruptions to the global markets. Given that we provide life-saving and life-enhancing products, we plan to continue operating in Russia provided we can safely do so. During the three months 2022 net sales in Russia were approximately 0.1% of our revenues. Although Russia does not constitute a material portion of our business, there is uncertainty around the impact it will have on the global economy, supply chains and fuel prices generally, and therefore our business. Refer to Part II, Item 1A. "Risk Factors" for further details.

China Volume-Based Procurement and Import Purchase Evaluation

The government in China has launched regional and national programs for volume-based procurement ("VBP") of high-value medical consumables to reduce healthcare costs. Each VBP program has specific requirements to award contracts to the lowest bidders who are able to satisfy the quality and quantity requirements. The successful bidders may be guaranteed sales volume for certain products, while unsuccessful bidders may lose unit sales volume. The prices required for a successful bid have negatively impacted our existing commercial operations of joint replacement and trauma products in China. To date our other businesses have not been significantly impacted, but may be in the future. We do not expect any significant impairments related to further VBP programs. China has also issued national guiding standards for Import Purchase Evaluation (IPE) which has increased the purchase of locally sourced equipment in China's public hospitals and is impacting our MedSurg business in China. Our business in China represented approximately 2.5% of our revenues for the three months 2022.

Overview of the Three Months

In the three months 2022 we achieved sales growth of 8.1% from 2021. Excluding the impact of acquisitions and divestitures sales grew 9.2% in constant currency. We reported operating income margin of 10.5%, net earnings of $323 and net earnings per diluted share of $0.84. Excluding the impact of certain items, adjusted operating income margin(1) contracted by 170 basis points to 21.8%, with adjusted net earnings(1) of $752 and adjusted net earnings per diluted share(1) of $1.97 representing growth of 2.1%.

Recent Developments

In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%.

In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. Refer to Note 7 to our Consolidated Financial Statements for further information.

Effective April 1, 2022 our subsidiaries in Turkey will begin accounting for their operations as highly inflationary, as required by United States Generally Accepted Accounting Principles, as the cumulative three year inflation rate in Turkey exceeded 100% in March 2022. We do not expect this change to have a material impact on our Consolidated Financial Statements. During the three months 2022 net sales in Turkey were less than 0.5% of our revenues.

(1) Refer to "Non-GAAP Financial Measures" for a discussion of non-GAAP financial measures used in this report and a reconciliation to the most directly comparable GAAP financial measure.

Dollar amounts are in millions except per share amounts or as otherwise specified. 10

STRYKER CORPORATION 2022 First Quarter Form 10-Q

CONSOLIDATED RESULTS OF OPERATIONS
	Three Months
					Percent Net Sales				Percentage
	2022		2021		2022		2021		Change
Net sales	$	4,275	$	3,953	100.0	%	100.0	%	8.1	%
Gross profit	2,734		2,509		64.0		63.5		9.0
Research, development and engineering expenses	413		288		9.7		7.3		43.4
Selling, general and administrative expenses	1,710		1,575		40.0		39.8		8.6
Recall charges	14		6		0.3		0.2		nm
Amortization of intangible assets	150		181		3.5		4.6		(17.1)
Other income (expense), net	(61)		(92)		(1.4)		(2.3)		(33.7)
Income taxes	63		65		nm		nm		(3.1)
Net earnings	$	323	$	302	7.6	%	7.6	%	7.0	%
Net earnings per diluted share	$	0.84	$	0.79					6.3	%
Adjusted net earnings per diluted share(1)	$	1.97	$	1.93					2.1	%

nm - not meaningful

Geographic and Segment Net Sales	Three Months
					Percentage Change
	2022		2021		As Reported		Constant Currency
Geographic:
United States	$	3,105	$	2,784	11.5	%	11.5	%
International	1,170		1,169		0.1		6.0
Total	$	4,275	$	3,953	8.1	%	9.9	%
Segment:
MedSurg and Neurotechnology	$	2,423	$	2,191	10.6	%	12.1	%
Orthopaedics and Spine	1,852		1,762		5.1		7.2
Total	$	4,275	$	3,953	8.1	%	9.9	%

Supplemental Net Sales Growth Information
	Three Months
					Percentage Change
									United States		International
	2022		2021		As Reported		Constant Currency		As Reported		As Reported		Constant Currency
MedSurg and Neurotechnology:
Instruments	$	528	$	469	12.6	%	14.1	%	16.6	%	0.2	%	6.2	%
Endoscopy	538		469		14.8		16.7		18.1		4.8		12.2
Medical	664		622		6.8		7.9		11.0		(6.7)		(2.4)
Neurovascular	301		289		3.9		6.5		(1.4)		7.2		11.5
Neuro Cranial	323		281		15.1		16.2		18.1		3.5		8.8
Other	69		61		12.3		12.3		11.8		45.7		46.1
	$	2,423	$	2,191	10.6	%	12.1	%	14.0	%	1.8	%	7.0	%
Orthopaedics and Spine:
Knees	$	464	$	412	12.5	%	14.6	%	17.5	%	0.1	%	7.3	%
Hips	327		309		5.9		8.6		8.5		1.9		8.7
Trauma and Extremities	685		640		7.1		9.0		10.6		(0.9)		5.3
Spine	279		278		0.1		1.8		3.7		(8.0)		(2.5)
Other	97		123		(20.4)		(18.9)		(23.3)		(10.9)		(4.2)
	$	1,852	$	1,762	5.1	%	7.2	%	8.2	%	(1.7)	%	4.8	%
Total	$	4,275	$	3,953	8.1	%	9.9	%	11.5	%	0.1	%	6.0	%

Consolidated Net Sales

Consolidated net sales increased 8.1% in the three months 2022 as reported and 9.9% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.8%. Excluding the 0.7% impact of acquisitions and divestitures, net sales in constant currency increased by 10.2% from increased unit volume partially offset by 1.0% due to lower prices. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology products and most Orthopaedics and Spine products.

MedSurg and Neurotechnology Net Sales

MedSurg and Neurotechnology net sales increased 10.6% in the three months 2022 as reported and 12.1% in constant currency, as foreign currency exchange rates negatively impacted net sales by 1.5%. Excluding the 1.3% impact of acquisitions, net sales in constant currency increased by 10.8% from increased unit volume. The unit volume increase was due to higher shipments across all MedSurg and Neurotechnology products.

Orthopaedics and Spine Net Sales

Orthopaedics and Spine net sales increased 5.1% in the three months 2022 as reported and 7.2% in constant currency, as foreign currency exchange rates negatively impacted net sales by

Dollar amounts are in millions except per share amounts or as otherwise specified. 11

STRYKER CORPORATION 2022 First Quarter Form 10-Q

2.1%. Net sales in constant currency increased 9.5% from increased unit volume partially offset by 2.3% from lower prices. The unit volume increase was due to higher shipments of hips, knees, trauma and extremities and spine products.

Gross Profit

Gross profit as a percentage of sales in the three months 2022 increased to 64.0% from 63.5% in 2021. Excluding the impact of the items noted below, gross profit decreased to 64.1% of sales in the three months 2022 from 65.4% in 2021 due to increased costs from inflationary pressures, primarily related to labor, electronic components, steel and transportation.

					Percent Net Sales
Three Months	2022		2021		2022		2021
Reported	$	2,734	$	2,509	64.0	%	63.5	%
Inventory stepped-up to fair value	5		79		0.1		2.0
Restructuring-related and other charges	2		(2)		—		(0.1)
Medical device regulations	—		1		—		—
Adjusted	$	2,741	$	2,587	64.1	%	65.4	%

Research, Development and Engineering Expenses

Research, development and engineering expenses increased $125 or 43.4% in the three months 2022 and increased as a percentage of sales to 9.7% from 7.3% in 2021. Excluding the impact of the items noted below, expenses increased to 7.2% of sales in 2022 from 6.8% in 2021.

The increases for the three months are due to disciplined ramp up in spending to facilitate our growth and new product development, investments in new technologies, integration of recent acquisitions and the write-off of certain intangible assets.

					Percent Net Sales
Three Months	2022		2021		2022		2021
Reported	$	413	$	288	9.7	%	7.3	%
Restructuring-related and other charges	(79)		—		(1.8)		—
Medical device regulations	(28)		(18)		(0.7)		(0.5)
Adjusted	$	306	$	270	7.2	%	6.8	%

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $135 or 8.6% in the three months 2022 and increased as a percentage of sales to 40.0% from 39.8% in 2021. Excluding the impact of the items noted below, expenses decreased to 35.1% of sales in 2022 from 35.2% in 2021. Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded.

					Percent Net Sales
Three Months	2022		2021		2022		2021
Reported	$	1,710	$	1,575	40.0	%	39.8	%
Other acquisition and integration-related	(144)		(170)		(3.3)		(4.2)
Restructuring-related and other charges	(28)		(15)		(0.7)		(0.4)
Regulatory and legal matters	(37)		—		(0.9)		—
Adjusted	$	1,501	$	1,390	35.1	%	35.2	%

Recall Charges

Recall charges were $14 in the three months 2022 and $6 in the three months 2021. Charges were primarily due to the previously disclosed Wright hip products. Refer to Note 6 to our Consolidated Financial Statements for further information.

Amortization of Intangible Assets

Amortization of intangible assets was $150 and $181 in the three months 2022 and 2021. Refer to Note 7 to our Consolidated Financial Statements for further information.

Operating Income

Operating income decreased $12 to 10.5% of sales in the three months 2022 from 11.6% of sales in 2021. Excluding the impact of the items noted below, operating income decreased to 21.8% of sales in 2022 from 23.5% in 2021 primarily due to higher costs from inflationary pressures.

					Percent Net Sales
Three Months	2022		2021		2022		2021
Reported	$	447	$	459	10.5	%	11.6	%
Inventory stepped-up to fair value	5		79		0.1		2.0
Other acquisition and integration-related	144		170		3.3		4.2
Amortization of purchased intangible assets	150		181		3.5		4.6
Restructuring-related and other charges	109		14		2.5		0.4
Medical device regulations	28		19		0.7		0.5
Recall-related matters	14		6		0.3		0.2
Regulatory and legal matters	37		—		0.9		—
Adjusted	$	934	$	928	21.8	%	23.5	%

Other Income (Expense), Net

Other income (expense), net was ($61) and ($92) in the three months 2022 and 2021. The decrease in net expense in 2022 was primarily due to favorable investment returns, favorable foreign exchange rates, and decreased interest expense driven by the repayment of senior unsecured notes that were due March 15, 2021 and the June 2021 repayment of the term loan due November 2023.

Income Taxes

Our effective tax rates were 16.3% and 17.7% in the three months 2022 and 2021. The change in the effective income tax rate for the three months was primarily due to lower tax expense from our operating structure and current profit mix.

We are routinely audited by income tax authorities in the jurisdictions we operate. It is reasonably possible within the next 12 months that uncertain tax positions, excluding interest, could decrease by as much as $175 as a result of the resolution of tax matters.

Net Earnings

Net earnings increased to $323 or $0.84 per diluted share in the three months 2022 from $302 or $0.79 per diluted share in 2021. Adjusted net earnings per diluted share(1) increased to $1.97 in 2022 from $1.93 in 2021. The impact of foreign currency exchange rates reduced net earnings per diluted share by approximately $0.09 in 2022 and increased net earnings per diluted share by approximately $0.06 in 2021.

					Percent Net Sales
Three Months	2022		2021		2022		2021
Reported	$	323	$	302	7.6	%	7.6	%
Inventory stepped-up to fair value	4		60		0.1		1.5
Other acquisition and integration-related	105		129		2.4		3.3
Amortization of purchased intangible assets	115		151		2.6		3.8
Restructuring-related and other charges	84		18		1.9		0.5
Medical device regulations	24		16		0.6		0.4
Recall-related matters	11		5		0.3		0.1
Regulatory and legal matters	28		—		0.7		—
Tax matters	58		56		1.4		1.4
Adjusted	$	752	$	737	17.6	%	18.6	%

Dollar amounts are in millions except per share amounts or as otherwise specified. 12

STRYKER CORPORATION 2022 First Quarter Form 10-Q

Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (GAAP) with certain non-GAAP financial measures, including percentage sales growth in constant currency; percentage organic sales growth; adjusted gross profit; adjusted selling, general and administrative expenses; adjusted research, development and engineering expenses; adjusted operating income; adjusted other income (expense), net; adjusted effective income tax rate; adjusted net earnings; adjusted net earnings per diluted share (Diluted EPS); free cash flow; and free cash flow conversion. We believe these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures. To measure percentage sales growth in constant currency, we remove the impact of changes in foreign currency exchange rates that affect the comparability and trend of sales. Percentage sales growth in constant currency is calculated by translating current and prior year results at the same foreign currency exchange rate. To measure percentage organic sales growth, we remove the impact of changes in foreign currency exchange rates, acquisitions and divestitures, which affect the comparability and trend of sales. Percentage organic sales growth is calculated by translating current year and prior year results at the same foreign currency exchange rates excluding the impact of acquisitions and divestitures. To measure earnings performance on a consistent and comparable basis, we exclude certain items that affect the comparability of operating results and the trend of earnings. To measure free cash flow, we adjust cash provided by operating activities by the amount of purchases of property, plant and equipment and proceeds from long-lived asset disposals and remove the impact of certain legal settlements and recall payments. To measure free cash flow conversion we divide free cash flow by adjusted net earnings. These adjustments are irregular in timing and may not be indicative of our past and future performance. The following are examples of the types of adjustments that may be included in a period:

1.Acquisition and integration-related costs. Costs related to integrating recently acquired businesses (e.g., costs associated with the termination of sales relationships, workforce reductions and other integration-related activities) and specific costs (e.g., inventory step-up and deal costs) related to the consummation of the acquisition process.

2.Amortization of purchased intangible assets. Periodic amortization expense related to purchased intangible assets.

3.Restructuring-related and other charges. Costs associated with the termination of sales relationships in certain countries, workforce reductions, elimination of product lines, certain long-lived and intangible asset write-offs and impairments and associated costs and other restructuring-related activities.

4.Medical device regulations. Costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the new medical device reporting regulations and other requirements of the European Union and the more stringent regulations for medical devices in China.

5.Recall-related matters. Our best estimate of the minimum of the range of probable loss to resolve the Rejuvenate, LFIT V40 and other product recalls.

6.Regulatory and legal matters. Our best estimate of the minimum of the range of probable loss to resolve certain regulatory matters and other legal settlements.

7.Tax matters. Charges represent the impact of accounting for certain significant and discrete tax items.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for reported sales growth, gross profit, selling, general and administrative expenses, research, development and engineering expenses, operating income, other income (expense), net, effective income tax rate, net earnings and net earnings per diluted share, the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures at the end of the discussion of Consolidated Results of Operations below. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The weighted-average diluted shares outstanding used in the calculation of non-GAAP net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period.

Dollar amounts are in millions except per share amounts or as otherwise specified. 13

STRYKER CORPORATION 2022 First Quarter Form 10-Q

Reconciliation of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Three Months 2022	Gross Profit			Selling, General & Administrative Expenses			Research, Development & Engineering Expenses			Operating Income			Other Income (Expense), Net			Net Earnings			Effective Tax Rate		Diluted EPS
Reported	$	2,734		$	1,710		$	413		$	447		$	(61)		$	323		16.3	%	$	0.84
Reported percent net sales	64.0		%	40.0		%	9.7		%	10.5		%	(1.4)		%	7.6		%
Acquisition and integration-related costs:
Inventory stepped-up to fair value	5			—			—			5			—			4			0.1		0.01
Other acquisition and integration-related	—			(144)			—			144			—			105			4.9		0.27
Amortization of purchased intangible assets	—			—			—			150			—			115			3.6		0.30
Restructuring-related and other charges	2			(28)			(79)			109			—			84			2.5		0.22
Medical device regulations	—			—			(28)			28			—			24			0.2		0.06
Recall-related matters	—			—			—			14			—			11			0.4		0.04
Regulatory and legal matters	—			(37)			—			37			—			28			1.0		0.08
Tax matters	—			—			—			—			—			58			(15.1)		0.15
Adjusted	$	2,741		$	1,501		$	306		$	934		$	(61)		$	752		13.9	%	$	1.97
Adjusted percent net sales	64.1		%	35.1		%	7.2		%	21.8		%	(1.4)		%	17.6		%

Three Months 2021	Gross Profit			Selling, General & Administrative Expenses			Research, Development & Engineering Expenses			Operating Income			Other Income (Expense), Net			Net Earnings			Effective Tax Rate		Diluted EPS
Reported	$	2,509		$	1,575		$	288		$	459		$	(92)		$	302		17.7	%	$	0.79
Reported percent net sales	63.5		%	39.8		%	7.3		%	11.6		%	(2.3)		%	7.6		%
Acquisition and integration-related costs:
Inventory stepped-up to fair value	79			—			—			79			—			60			2.3		0.16
Other acquisition and integration-related	—			(170)			—			170			—			129			5.1		0.34
Amortization of purchased intangible assets	—			—			—			181			—			151			2.2		0.40
Restructuring-related and other charges	(2)			(15)			—			14			11			18			1.0		0.05
Medical device regulations	1			—			(18)			19			—			16			0.3		0.04
Recall-related matters	—			—			—			6			—			5			(0.5)		0.01
Regulatory and legal matters	—			—			—			—			—			—			—		—
Tax matters	—			—			—			—			—			56			(15.1)		0.14
Adjusted	$	2,587		$	1,390		$	270		$	928		$	(81)		$	737		13.0	%	$	1.93
Adjusted percent net sales	65.4		%	35.2		%	6.8		%	23.5		%	(2.0)		%	18.6		%

FINANCIAL CONDITION AND LIQUIDITY

Three Months	2022		2021
Net cash provided by operating activities	$	203	$	452
Net cash used in investing activities	(2,682)		(96)
Net cash provided by (used in) financing activities	993		(1,053)
Effect of exchange rate changes on cash and cash equivalents	—		(8)
Change in cash and cash equivalents	$	(1,486)	$	(705)

Operating Activities

Cash provided by operating activities was $203 and $452 in the three months 2022 and 2021. The decrease was primarily due to changes in working capital.

Investing Activities    

Cash used in investing activities was $2,682 and $96 in the three months 2022 and 2021. The increase in cash used in 2022 was primarily due to increased payments for acquisitions.

Financing Activities

Cash provided by (used in) financing activities was $993 and ($1,053) in the three months 2022 and 2021. Cash provided in 2022 was primarily driven by the issuance of a $1,500 term loan used to fund the Vocera acquisition and the issuance of commercial paper, partially offset by the payment of dividends. Cash used by financing activities in the three months 2021 was primarily due to debt repayments of $750 in March 2021. We did not repurchase any shares in the three months 2022 or 2021.

Three Months	2022		2021
Total dividends paid to common shareholders	$	262	$	238

Liquidity

Cash, cash equivalents and marketable securities were $1,530 and $3,019 on March 31, 2022 and December 31, 2021. Current

assets exceeded current liabilities by $4,317 and $5,468 on March 31, 2022 and December 31, 2021. We anticipate being able to support our short-term liquidity and operating needs from a variety of sources including cash from operations, commercial paper and existing credit lines.

We raised funds in the capital markets in the past and may continue to do so from time-to-time. We continue to have strong investment-grade short-term and long-term debt ratings that we believe should enable us to refinance our debt as needed.

Our cash, cash equivalents and marketable securities held in locations outside the United States was approximately 44% on March 31, 2022 compared to 26% on December 31, 2021.

Critical Accounting Policies

There were no changes to our critical accounting policies from those disclosed in our Annual Report on Form 10-K for 2021.

New Accounting Pronouncements Not Yet Adopted

Refer to Note 1 to our Consolidated Financial Statements for information.

Guarantees and Other Off-Balance Sheet Arrangements

We do not have guarantees or other off-balance sheet financing arrangements, including variable interest entities, of a magnitude that we believe could have a material impact on our financial condition or liquidity.

OTHER MATTERS

Legal and Regulatory Matters

We are involved in various ongoing proceedings, legal actions and claims arising in the normal course of our business, including proceedings related to product, labor, intellectual property and

Dollar amounts are in millions except per share amounts or as otherwise specified. 14

STRYKER CORPORATION 2022 First Quarter Form 10-Q

other matters. Refer to Note 6 to our Consolidated Financial Statements for further information.

FORWARD-LOOKING STATEMENTS

This report contains statements referring to us that are not historical facts and are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, which are intended to take advantage of the "safe harbor" provisions of the Reform Act, are based on current projections about operations, industry conditions, financial condition and liquidity. Words that identify forward-looking statements include words such as "may," "could," "will," "should," "possible," "plan," "predict," "forecast," "potential," "anticipate," "estimate," "expect," "project," "intend," "believe," "may impact," "on track," "goal," "strategy" and words and terms of similar substance used in connection with any discussion of future operating or financial performance, an acquisition or our businesses. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Those statements are not guarantees and are subject to risks, uncertainties and assumptions that are difficult to predict, including uncertainties related to the impact of the COVID-19 pandemic on our operations and financial results. Therefore, actual results could differ materially and adversely from these forward-looking statements. Some important factors that could cause our actual results to differ from our expectations in any forward-looking statements include those risks discussed in Item 1A. "Risk Factors" of our Annual Report on Form 10-K for 2021. This Form 10-Q should be read in conjunction with our Consolidated Financial Statements and accompanying notes to our Consolidated Financial Statements in our Annual Report on Form 10-K for 2021. We disclaim any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that affect the likelihood that actual results will differ from those contained in the forward-looking statements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We consider our greatest potential areas of market risk exposure to be exchange rate risk and the impacts of the COVID-19 pandemic on our operations and financial results. Quantitative and qualitative disclosures about exchange rate risk are included in Item 7A "Quantitative and Qualitative Disclosures About Market Risk" of our Annual Report on Form 10-K for 2021. There were no material changes from the information provided therein. We are not able to quantify the impacts of the COVID-19 pandemic on our financial results. Qualitative disclosures about the COVID-19 pandemic are included in Part I, Item 2 "Management's Discussion and Analysis of Financial Condition and Results of Operations" of this Form 10-Q and Part I, Item 1A "Risk Factors" of our Annual Report on Form 10-K for 2021.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of the Chief Executive Officer and Chief Financial Officer (the Certifying Officers), evaluated the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended) on March 31, 2022. Based on that evaluation, the

Certifying Officers concluded the Company's disclosure controls and procedures were effective as of March 31, 2022.

Changes in Internal Control Over Financial Reporting

There was no change to our internal control over financial reporting during the three months 2022 that materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. In February 2022, we completed the acquisition of Vocera and are currently integrating Vocera into our operations, compliance programs and internal control processes. Vocera constituted approximately 8.5% of our total assets as of March 31, 2022, including the goodwill and intangible assets recorded as part of the purchase price allocation and less than 1% of our net sales in the three months ended March 31, 2022. United States Securities and Exchange Commission guidance allows companies to exclude acquisitions from their assessment of the internal control over financial reporting during the first year following an acquisition while integrating the acquired company. We have excluded the acquired operations of Vocera from our assessment of the Company's internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1A. RISK FACTORS

We are not aware of any material changes to the risk factors included in Item 1A. "Risk Factors" in our Annual Report on Form 10-K for 2021, except for the addition of the following risk factor:

The ongoing conflict between Russia and Ukraine, and the global response to it, may adversely affect our business and results of operations: The military conflict between Russia and Ukraine has resulted in the implementation of sanctions by the United States and other governments against Russia and has caused significant volatility and disruptions to the global markets. It is not possible to predict the short- and long-term implications of this conflict, which could include but are not limited to further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, supply chain challenges and adverse effects on currency exchange rates and financial markets. In addition, the United States government reported that United States sanctions against Russia in response to the conflict could lead to an increased threat of cyberattacks against United States companies. These increased threats could pose risks to the security of our Information Technology systems, networks and product offerings, as well as the confidentiality, availability and integrity of our data. Further, if the conflict develops beyond Ukraine or further intensifies, it could have an adverse impact on our operations in Poland or other affected areas. We are continuing to monitor the situation in Ukraine and globally as well as assess its potential impact on our business. Although Russia does not constitute a material portion of our business, a significant escalation or further expansion of the conflict's current scope or related disruptions to the global markets could have a material adverse effect on our results of operations.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We issued 10,587 shares of our common stock in the three months 2022 as performance incentive awards to employees. These shares are not registered under the Securities Act of 1933 based on the conclusion that the awards would not be events of sale within the meaning of Section 2(a)(3) of the Act.

In March 2015 we announced that our Board of Directors had authorized us to purchase up to $2,000 of our common stock. The manner, timing and amount of repurchases are determined

Dollar amounts are in millions except per share amounts or as otherwise specified. 15

by management based on an evaluation of market conditions, stock price, and other factors and are subject to regulatory considerations. Purchases are made from time to time in the open market, in privately negotiated transactions or otherwise.

In the three months 2022 we did not repurchase any shares of our common stock under our authorized repurchase program. The total dollar value of shares of our common stock that could be acquired under our authorized repurchase program was $1,033 as of March 31, 2022.

ITEM 6. EXHIBITS

2(i)**	Agreement and Plan of Merger, dated as of January 6, 2022, by and among Stryker Corporation, Voice Merger Sub Corp., and Vocera Communications, Inc. — Incorporated by reference to Exhibit 2.1 to the Company's Form 8-K dated January 11, 2022 (Commission File No. 001-13149).
10(i)	Term Loan Agreement, dated as of February 22, 2022, among Stryker Corporation, as borrower, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent — Incorporated by reference to Exhibit 10.1 to the Company's Form 8-K dated February 25, 2022 (Commission File No. 001-13149).
31(i)	Certification of Principal Executive Officer of Stryker Corporation pursuant to Rule 13a-14(a).
31(ii)	Certification of Principal Financial Officer of Stryker Corporation pursuant to Rule 13a-14(a).
32(i)*	Certification by Principal Executive Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
32(ii)*	Certification by Principal Financial Officer of Stryker Corporation pursuant to 18 U.S.C. Section 1350.
101.INS	iXBRL Instance Document
101.SCH	iXBRL Schema Document
101.CAL	iXBRL Calculation Linkbase Document
101.DEF	iXBRL Definition Linkbase Document
101.LAB	iXBRL Label Linkbase Document
101.PRE	iXBRL Presentation Linkbase Document
104	Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
	* Furnished with this Form 10-Q
	** Schedules have been omitted pursuant to Item 601 (b)(2) of Regulation S-K. Stryker Corporation hereby undertakes to furnish supplementally copies of any of the omitted schedules upon request by the United States Securities and Exchange Commission.

Dollar amounts are in millions except per share amounts or as otherwise specified. 16

STRYKER CORPORATION 2022 First Quarter Form 10-Q

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		STRYKER CORPORATION
		(Registrant)
Date:	April 29, 2022	/s/ KEVIN A. LOBO
		Kevin A. Lobo
		Chair, Chief Executive Officer and President
Date:	April 29, 2022	/s/ GLENN S. BOEHNLEIN
		Glenn S. Boehnlein
		Vice President, Chief Financial Officer

17

EX-31.1

Exhibit 31(i)

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Kevin A. Lobo, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:	April 29, 2022	/s/ KEVIN A. LOBO
		Kevin A. Lobo
		Chair, Chief Executive Officer and President

EX-31.2

Exhibit 31(ii)

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002

I, Glenn S. Boehnlein, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended March 31, 2022 of Stryker Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date:	April 29, 2022	/s/ GLENN S. BOEHNLEIN
		Glenn S. Boehnlein
		Vice President, Chief Financial Officer

EX-32.1

Exhibit 32(i)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Stryker Corporation (the "Company") for the quarter ended March 31, 2022 (the "Report"), I, Kevin A. Lobo, Chair and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	April 29, 2022	/s/ KEVIN A. LOBO
		Kevin A. Lobo
		Chair, Chief Executive Officer and President

EX-32.2

Exhibit 32(ii)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Stryker Corporation (the "Company") for the quarter ended March 31, 2022 (the "Report"), I, Glenn S. Boehnlein, Vice President, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date:	April 29, 2022	/s/ GLENN S. BOEHNLEIN
		Glenn S. Boehnlein
		Vice President, Chief Financial Officer

XML

Document and Entity Information	3 Months Ended
	Mar. 31, 2022 shares
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	001-13149
Entity Registrant Name	STRYKER CORP
Entity Incorporation, State or Country Code	MI
Entity Tax Identification Number	38-1239739
Entity Address, Address Line One	2825 Airview Boulevard
Entity Address, City or Town	Kalamazoo,
Entity Address, State or Province	MI
Entity Address, Postal Zip Code	49002
City Area Code	(269)
Local Phone Number	385-2600
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	378,154,080
Amendment Flag	false
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q1
Entity Central Index Key	0000310764
Current Fiscal Year End Date	--12-31
Common Stock
Document Information [Line Items]
Title of each class	Common Stock, $.10 Par Value
Trading Symbol	SYK
Security Exchange Name	NYSE
Senior Unsecured Notes 1.125% due 2021
Document Information [Line Items]
Title of each class	1.125% Notes due 2023
Trading Symbol	SYK23
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.250% Due 2024
Document Information [Line Items]
Title of each class	0.250% Notes due 2024
Trading Symbol	SYK24A
Security Exchange Name	NYSE
Senior Unsecured Notes 2.125% due 2027
Document Information [Line Items]
Title of each class	2.125% Notes due 2027
Trading Symbol	SYK27
Security Exchange Name	NYSE
Senior Unsecured Notes, 0.750% Due 2029
Document Information [Line Items]
Title of each class	0.750% Notes due 2029
Trading Symbol	SYK29
Security Exchange Name	NYSE
Senior Unsecured Notes 2.625% due 2030
Document Information [Line Items]
Title of each class	2.625% Notes due 2030
Trading Symbol	SYK30
Security Exchange Name	NYSE
Senior Unsecured Notes, 1.000% Due 2031
Document Information [Line Items]
Title of each class	1.000% Notes due 2031
Trading Symbol	SYK31
Security Exchange Name	NYSE

XML

Consolidated Statements Of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Statement [Abstract]
Net sales	$ 4,275	$ 3,953
Cost of sales	1,541	1,444
Gross profit	2,734	2,509
Research, development and engineering expenses	413	288
Selling, general and administrative expenses	1,710	1,575
Recall charges	14	6
Amortization of intangible assets	150	181
Total operating expenses	2,287	2,050
Operating income	447	459
Other income (expense), net	(61)	(92)
Earnings before income taxes	386	367
Income taxes	63	65
Net earnings	$ 323	$ 302
Net earnings per share of common stock:
Basic	$ 0.86	$ 0.80
Diluted	$ 0.84	$ 0.79
Weighted-average shares outstanding (in millions):
Basic	377.7	376.3
Effect of dilutive employee stock compensation	5.0	5.4
Diluted	382.7	381.7
Cash dividends declared per share of common stock (in dollars per share)	$ 0.695	$ 0.63

XML

Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Statement of Comprehensive Income [Abstract]
Net earnings	$ 323	$ 302
Other comprehensive income (loss), net of tax:
Marketable securities	(1)	0
Pension plans	(1)	7
Unrealized gains (losses) on designated hedges	1	28
Financial statement translation	53	255
Total other comprehensive income (loss), net of tax	52	290
Comprehensive income	$ 375	$ 592

XML

Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash and cash equivalents	$ 1,458	$ 2,944
Marketable securities	72	75
Accounts receivable, less allowance of $140 ($167 in 2021)	2,991	3,022
Inventories:
Materials and supplies	750	691
Work in process	298	264
Finished goods	2,477	2,359
Total inventories	3,525	3,314
Prepaid expenses and other current assets	679	662
Total current assets	8,725	10,017
Property, plant and equipment:
Land, buildings and improvements	1,708	1,656
Machinery and equipment	3,824	3,842
Total property, plant and equipment	5,532	5,498
Less accumulated depreciation	2,739	2,665
Property, plant and equipment, net	2,793	2,833
Goodwill	15,228	12,918
Other intangibles, net	5,430	4,840
Noncurrent deferred income tax assets	1,602	1,760
Other noncurrent assets	2,359	2,263
Total assets	36,137	34,631
Current liabilities
Accounts payable	1,084	1,129
Accrued compensation	703	1,092
Income taxes	173	192
Dividends payable	263	263
Accrued product liabilities	430	401
Accrued expenses and other liabilities	1,541	1,465
Current maturities of debt	214	7
Total current liabilities	4,408	4,549
Long-term debt, excluding current maturities	13,885	12,472
Income taxes	917	913
Other noncurrent liabilities	1,881	1,820
Total liabilities	21,091	19,754
Shareholders' equity
Common stock, $0.10 par value	38	38
Additional paid-in capital	1,947	1,890
Retained earnings	13,540	13,480
Accumulated other comprehensive loss	(479)	(531)
Total shareholders' equity	15,046	14,877
Total liabilities and shareholders' equity	$ 36,137	$ 34,631
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

XML

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 140	$ 167
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10

XML

Consolidated Statements Of Shareholders' Equity (Unaudited) - USD ($) shares in Millions, $ in Millions	Total	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Dec. 31, 2020		$ 38	$ 1,741	$ 12,462	$ (1,157)
Beginning balance (in shares) at Dec. 31, 2020		376.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans		$ 0	(3)
Issuance of common stock under stock option and benefit plans (in shares)		0.6
Share-based compensation			68
Net earnings	$ 302			302
Cash dividends declared				(239)
Other comprehensive income (loss)	290				290
Ending balance at Mar. 31, 2021	13,502	$ 38	1,806	12,525	(867)
Ending balance (in shares) at Mar. 31, 2021		376.7
Beginning balance at Dec. 31, 2021	14,877	$ 38	1,890	13,480	(531)
Beginning balance (in shares) at Dec. 31, 2021		377.5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under stock compensation and benefit plans		$ 0	(14)
Issuance of common stock under stock option and benefit plans (in shares)		0.7
Share-based compensation			71
Net earnings	323			323
Cash dividends declared				(263)
Other comprehensive income (loss)	52				52
Ending balance at Mar. 31, 2022	$ 15,046	$ 38	$ 1,947	$ 13,540	$ (479)
Ending balance (in shares) at Mar. 31, 2022		378.2

XML

Consolidated Statements Of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities
Net earnings	$ 323	$ 302
Adjustments to reconcile net earnings to net cash provided by operating activities:
Depreciation	92	95
Amortization of intangible assets	150	181
Share-based compensation	71	68
Recall charges	14	6
Sale of inventory stepped-up to fair value at acquisition	5	79
Changes in operating assets and liabilities:
Accounts receivable	53	65
Inventories	(229)	(73)
Accounts payable	(52)	(37)
Accrued expenses and other liabilities	(348)	(178)
Recall-related payments	(9)	(8)
Income taxes	(3)	6
Other, net	136	(54)
Net cash provided by operating activities	203	452
Investing activities
Acquisitions, net of cash acquired	(2,563)	(27)
Purchases of marketable securities	(9)	(5)
Proceeds from sales of marketable securities	11	12
Purchases of property, plant and equipment	(119)	(83)
Other investing, net	(2)	7
Net cash used in investing activities	(2,682)	(96)
Financing activities
Proceeds (payments) on short-term borrowings, net	(170)	2
Proceeds from issuance of long-term debt	1,500	5
Payments on long-term debt	0	(750)
Payments of dividends	(262)	(238)
Cash paid for taxes from withheld shares	(72)	(53)
Other financing, net	(3)	(19)
Net cash provided by (used in) financing activities	993	(1,053)
Effect of exchange rate changes on cash and cash equivalents	0	(8)
Change in cash and cash equivalents	(1,486)	(705)
Cash and cash equivalents at beginning of period	2,944	2,943
Cash and cash equivalents at end of period	$ 1,458	$ 2,238

XML

Basis Of Presentation

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Basis of Presentation

BASIS OF PRESENTATION

General Information

Management believes the accompanying unaudited Consolidated Financial Statements contain all adjustments, including normal recurring items, considered necessary to fairly present the financial position of Stryker Corporation and its consolidated subsidiaries ("Stryker," the "Company," "we," "us" or "our") on March 31, 2022 and the results of operations for the three months 2022. The results of operations included in these Consolidated Financial Statements may not necessarily be indicative of our annual results. These statements should be read in conjunction with our Annual Report on Form 10-K for 2021.

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

New Accounting Pronouncements Recently Adopted

On January 1, 2022 we adopted ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

XML

Revenue Recognition

3 Months Ended

Mar. 31, 2022

Revenue Recognition [Abstract]

Revenue Recognition

REVENUE RECOGNITION

Our policies for recognizing sales have not changed from those described in our Annual Report on Form 10-K for 2021.

We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.

Net Sales by Product Line
	Three Months
	2022		2021
MedSurg and Neurotechnology:
Instruments	$	528	$	469
Endoscopy	538		469
Medical	664		622
Neurovascular	301		289
Neuro Cranial	323		281
Other	69		61
	$	2,423	$	2,191
Orthopaedics and Spine:
Knees	$	464	$	412
Hips	327		309
Trauma and Extremities	685		640
Spine	279		278
Other	97		123
	$	1,852	$	1,762
Total	$	4,275	$	3,953

Net Sales by Geography
	Three Months 2022				Three Months 2021
	United States		International		United States		International
MedSurg and Neurotechnology:
Instruments	$	414	$	114	$	355	$	114
Endoscopy	418		120		354		115
Medical	525		139		473		149
Neurovascular	110		191		111		178
Neuro Cranial	264		59		224		57
Other	68		1		60		1
	$	1,799	$	624	$	1,577	$	614
Orthopaedics and Spine:
Knees	$	345	$	119	$	294	$	118
Hips	202		125		186		123
Trauma and Extremities	487		198		440		200
Spine	200		79		193		85
Other	72		25		94		29
	$	1,306	$	546	$	1,207	$	555
Total	$	3,105	$	1,170	$	2,784	$	1,169

Contract Assets and Liabilities

On March 31, 2022 and December 31, 2021 contract assets recorded in our Consolidated Balance Sheets were not significant.

Our contract liabilities arise as a result of consideration received from customers at inception of contracts for certain businesses or where the timing of billing for services precedes satisfaction of our performance obligations. We generally satisfy performance obligations within one year from the contract inception date. Our contract liabilities were $635 and $529 on March 31, 2022 and December 31, 2021.

XML

Accumulated Other Comprehensive (Loss) Income (AOCI)

3 Months Ended

Mar. 31, 2022

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Accumulated Other Comprehensive (Loss) Income (AOCI)

ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME (AOCI)

Three Months 2022	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	—	$	(155)	$	40	$	(416)	$	(531)
OCI	(1)		(4)		4		86		85
Income taxes	—		2		(2)		(25)		(25)
Reclassifications to:
Other (income) expense	—		2		(1)		(11)		(10)
Income taxes	—		(1)		—		3		2
Net OCI	$	(1)	$	(1)	$	1	$	53	$	52
Ending	$	(1)	$	(156)	$	41	$	(363)	$	(479)

Three Months 2021	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(259)	$	(10)	$	(885)	$	(1,157)
OCI	—		8		27		273		308
Income taxes	—		(4)		(8)		(12)		(24)
Reclassifications to:
Cost of sales	—		—		1		—		1
Other (income) expense	—		4		10		(8)		6
Income taxes	—		(1)		(2)		2		(1)
Net OCI	$	—	$	7	$	28	$	255	$	290
Ending	$	(3)	$	(252)	$	18	$	(630)	$	(867)

XML

Derivative Instruments

3 Months Ended

Mar. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative Instruments

DERIVATIVE INSTRUMENTSWe use operational and economic hedges, foreign currency exchange forward contracts, net investment hedges (both derivative and non-derivative financial instruments) and interest rate derivative instruments to manage the impact of currency

exchange and interest rate fluctuations on earnings, cash flow and equity. We do not enter into derivative instruments for speculative purposes. We are exposed to potential credit loss in the event of nonperformance by our counterparties on our outstanding derivative instruments but do not anticipate nonperformance by any of our counterparties. Should a counterparty default, our maximum loss exposure is the asset balance of the instrument. We have not changed our hedging strategies, accounting practices or objectives from those disclosed in our Annual Report on Form 10-K for 2021.

Foreign Currency Hedges

March 2022	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	711	$	2,224	$	3,993	$	6,928
Maximum term in years							4.6
Fair value:
Other current assets	$	16	$	49	$	33	$	98
Other noncurrent assets	1		74		—		75
Other current liabilities	(7)		—		(29)		(36)
Other noncurrent liabilities	(1)		—		—		(1)
Total fair value	$	9	$	123	$	4	$	136

December 2021	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	973	$	2,266	$	5,512	$	8,751
Maximum term in years							4.9
Fair value:
Other current assets	$	15	$	39	$	92	$	146
Other noncurrent assets	1		65		—		66
Other current liabilities	(7)		—		(10)		(17)
Total fair value	$	9	$	104	$	82	$	195

We had €2.0 billion at March 31, 2022 and December 31, 2021 in certain foreign currency forward contracts designated as net investment hedges to hedge a portion of our investments in certain of our entities with functional currencies denominated in Euros. In addition to these derivative financial instruments designated as net investment hedges, we had €4.4 billion at March 31, 2022 and December 31, 2021 of senior unsecured notes designated as net investment hedges to selectively hedge portions of our investment in certain international subsidiaries. The currency effects of our Euro-denominated senior unsecured notes are reflected in AOCI within shareholders' equity where they offset gains and losses recorded on our net investment in international subsidiaries.

On March 31, 2022 the total after tax gain (loss) in AOCI related to designated net investment hedges was $42.

Net Currency Exchange Rate Gains (Losses)

Derivative		Three Months
instrument:	Recorded in:	2022		2021
Cash Flow	Cost of sales	$	—	$	(1)
Net Investment	Other income (expense), net	11		8
Non-Designated	Other income (expense), net	1		(2)
	Total	$	12	$	5

Pretax gains (losses) on derivatives designated as cash flow hedges of $13 and net investment hedges of $34 recorded in AOCI are expected to be reclassified to cost of sales and other income (expense), net in earnings within 12 months as of March 31, 2022. This cash flow hedge reclassification is primarily due to the sale of inventory that includes previously hedged purchases. A component of the AOCI amounts related to net investment hedges is reclassified over the life of the hedge instruments as we elected to exclude the initial value of the

component related to the spot-forward difference from the effectiveness assessment.

Interest Rate Hedges

Pretax gains of $5 recorded in AOCI related to other interest rate hedges closed in conjunction with debt issuances are expected to be reclassified to other income (expense), net in earnings within 12 months of March 31, 2022. The cash flow effect of interest rate hedges is recorded in cash flow from operations.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Fair Value Measurements

FAIR VALUE MEASUREMENTS

Our policies for managing risk related to foreign currency, interest rates, credit and markets and our process for determining fair value have not changed from those described in our Annual Report on Form 10-K for 2021.

There were no significant transfers into or out of any level of the fair value hierarchy in 2022.

Assets Measured at Fair Value	March		December
	2022		2021
Cash and cash equivalents	$	1,458	$	2,944
Trading marketable securities	182		193
Level 1 - Assets	$	1,640	$	3,137
Available-for-sale marketable securities:
Corporate and asset-backed debt securities	$	49	$	48
Foreign government debt securities	2		2
United States agency debt securities	5		5
United States Treasury debt securities	14		19
Certificates of deposit	2		1
Total available-for-sale marketable securities	$	72	$	75
Foreign currency exchange forward contracts	173		212
Level 2 - Assets	$	245	$	287
Total assets measured at fair value	$	1,885	$	3,424

Liabilities Measured at Fair Value	March		December
	2022		2021
Deferred compensation arrangements	$	182	$	193
Level 1 - Liabilities	$	182	$	193
Foreign currency exchange forward contracts	$	37	$	17
Level 2 - Liabilities	$	37	$	17
Contingent consideration:
Beginning	$	306	$	393
Additions	—		62
Change in estimate	(17)		(1)
Settlements	(4)		(148)
Ending	$	285	$	306
Level 3 - Liabilities	$	285	$	306
Total liabilities measured at fair value	$	504	$	516

Fair Value of Available for Sale Securities by Maturity
	March 2022		December 2021
Due in one year or less	$	40	$	36
Due after one year through three years	$	32	$	39

On March 31, 2022 and December 31, 2021 the aggregate difference between the cost and fair value of available-for-sale marketable securities was nominal. Interest and marketable securities income was $15 and $17 in the three months 2022 and 2021, which was recorded in other income (expense), net.

Our investments in available-for-sale marketable securities had a minimum credit quality rating of A2 (Moody's), A (Standard & Poor's) and A (Fitch). We do not plan to sell the investments, and it is not more likely than not that we will be required to sell the investments before recovery of their amortized cost basis, which may be maturity.

XML

Contingencies and Commitments

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Contingencies and Commitments

CONTINGENCIES AND COMMITMENTSWe are involved in various ongoing proceedings, legal actions and claims arising in the normal course of business, including proceedings related to product, labor, intellectual property and other matters, the most significant of which are more fully

described below. The outcomes of these matters will generally not be known for prolonged periods of time. In certain of the legal proceedings the claimants seek damages as well as other compensatory and equitable relief that could result in the payment of significant claims and settlements and/or the imposition of injunctions or other equitable relief. For legal matters for which management had sufficient information to reasonably estimate our future obligations, a liability representing management's best estimate of the probable loss, or the minimum of the range of probable losses when a best estimate within the range is not known, is recorded. The estimates are based on consultation with legal counsel, previous settlement experience and settlement strategies. If actual outcomes are less favorable than those estimated by management, additional expense may be incurred, which could unfavorably affect future operating results. We are self-insured for certain claims and expenses. The ultimate cost to us with respect to product liability claims could be materially different than the amount of the current estimates and accruals and could have a material adverse effect on our financial position, results of operations and cash flows.

In April 2022 the United States District Court for the District of Delaware issued a judgment following a jury verdict in favor of PureWick Corporation (PureWick) for its 2019 complaint seeking patent infringement damages related to our PrimaFit and PrimoFit products. The court awarded damages and we recorded charges of $28 in March 2022. If PureWick seeks enhancement of the judgment and is successful, the judgment could total approximately $100 and include an injunction against future sales. We intend to appeal the outcome of this case.

Recall Matters

In June 2012 we voluntarily recalled our Rejuvenate and ABG II Modular-Neck hip stems and terminated global distribution of these hip products. Product liability lawsuits relating to this voluntary recall have been filed against us. In November 2014 we entered into a settlement agreement to compensate eligible United States patients who had revision surgery prior to November 3, 2014 and in December 2016 the settlement program was extended to patients who had revision surgery prior to December 19, 2016. In September 2020 we entered into a second settlement agreement to compensate eligible United States patients who had revision surgery prior to September 9, 2020. We continue to offer support for recall-related care and reimburse patients who are not eligible to enroll in the settlement program for testing and treatment services, including any necessary revision surgeries. In addition, there are remaining lawsuits that we will continue to defend against.

In August 2016 and May 2018 we voluntarily recalled certain lot-specific sizes and offsets of LFIT Anatomic CoCr V40 Femoral Heads. Product liability lawsuits and claims relating to this voluntary recall have been filed against us. In November 2018 we entered into a settlement agreement to resolve a significant number of claims and lawsuits related to the recalls. In April 2022 we executed a second agreement to resolve a significant number of claims and lawsuits related to the recalls. The specific terms of the settlement agreement, including the financial terms, are confidential.

With the acquisition of Wright Medical Group N.V. (Wright) in November 2020, we are responsible for certain product liability claims, primarily related to certain hip products sold by Wright prior to its 2014 divestiture of the OrthoRecon business. We will continue to evaluate each claim and the possible loss we may incur.

We have incurred, and expect to incur in the future, costs associated with the defense and settlement of these matters. For the three months 2022 we have recorded charges of $14 and made payments of $9, primarily related to Wright hip products. Based on the information that has been received, we have estimated the remaining range of probable loss related to recall matters globally to be approximately $385 to $520. We have recorded reserves representing the remaining minimum of the range of probable loss. The final outcomes of these matters are dependent on many factors that are difficult to predict. Accordingly, the ultimate cost related to these matters may be materially different than the amount of our current estimate and accruals and could have a material adverse effect on our results of operations and cash flows.

Leases	March			December
	2022			2021
Right-of-use assets	$	490		$	419
Lease liabilities, current	$	129		$	112
Lease liabilities, non-current	$	370		$	310
Other information:
Weighted-average remaining lease term	5.5 years			5.4 years
Weighted-average discount rate	2.65		%	2.86		%

	Three Months
	2022		2021
Operating lease cost	$	31	$	36

XML

Acquisitions

3 Months Ended

Mar. 31, 2022

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

We acquire stock in companies and various assets that continue to support our capital deployment and product development strategies. The aggregate purchase price of our acquisitions, net of cash acquired was $2,563 and $31 in the three months 2022 and 2021.

In February 2022 we completed the acquisition of Vocera Communications, Inc. (Vocera) for $79.25 per share, or an aggregate purchase price of $2.6 billion, net of cash acquired ($3.0 billion including convertible notes). Vocera is a leader in the digital care coordination and communication category. Vocera is part of our Medical business within MedSurg and Neurotechnology. Goodwill attributable to the acquisition reflects the strategic benefits of expanding our presence in adjacent markets, diversifying our product portfolio, advancing innovations, and accelerating our digital aspirations. This goodwill is not deductible for tax purposes.

In the three months 2022 note holders elected to redeem the 1.50% and 0.50% convertible notes assumed in the Vocera acquisition for $101 and $324. These repayments are classified as financing activities in the Consolidated Statements of Cash Flows.

Share-based awards for Vocera employees vested upon our acquisition and a charge of $132 was recorded in selling, general and administrative expenses.

Purchase price allocations for our significant acquisitions are:

Purchase Price Allocation of Acquired Net Assets
2022	Vocera
Tangible assets and liabilities:
Accounts receivable	$	33
Inventory	13
Deferred income tax assets	70
Other assets	92
Debt	(425)
Deferred income tax liabilities	(183)
Other liabilities	(115)
Intangible assets:
Customer and distributor relationships	550
Developed technology and patents	178
Trade name	18
Goodwill	2,332
Purchase price, net of cash acquired of $281	$	2,563
Weighted-average life of intangible assets	13

Purchase price allocations for Vocera were based on preliminary valuations, primarily related to intangible assets and deferred income taxes. Our estimates and assumptions are subject to change within the measurement period.

Consolidated Estimated Amortization Expense
Remainder of 2022		2023		2024		2025		2026
$	484	$	624	$	594	$	573	$	515

XML

Debt and Credit Facilities

3 Months Ended

Mar. 31, 2022

Long-term Debt, Unclassified [Abstract]

Debt And Credit Facilities

DEBT AND CREDIT FACILITIES

We have lines of credit issued by various financial institutions that are available to fund our day-to-day operating needs. Certain of our credit facilities require us to comply with financial and other covenants. We were in compliance with all covenants on March 31, 2022.

In February 2022 we entered into a $1.5 billion term loan agreement that matures on February 22, 2025 and bears interest at a base rate based on the Term Secured Overnight Financing Rate (SOFR) plus 0.725%.

In the first quarter of 2022 our Board of Directors approved an increase to the maximum amount of commercial paper that can be outstanding from $1,500 to $2,250.

On March 31, 2022 we had $195 outstanding under our commercial paper programs which allows for maturities up to 397 days from the date of issuance.

Summary of Total Debt			March 2022		December 2021
	Rate	Due
Senior unsecured notes:
	1.125%	November 30, 2023	$	610	$	622
	0.600%	December 1, 2023	594		598
	3.375%	May 15, 2024	598		593
	0.250%	December 3, 2024	941		958
	1.150%	June 15, 2025	646		645
	3.375%	November 1, 2025	748		748
	3.500%	March 15, 2026	994		994
	2.125%	November 30, 2027	829		845
	3.650%	March 7, 2028	597		597
	0.750%	March 1, 2029	885		901
	1.950%	June 15, 2030	990		990
	2.625%	November 30, 2030	714		727
	1.000%	December 3, 2031	824		840
	4.100%	April 1, 2043	392		392
	4.375%	May 15, 2044	395		395
	4.625%	March 15, 2046	982		982
	2.900%	June 15, 2050	642		642
Term loan		February 22, 2025	1,500		—
Commercial paper			195		—
Other			23		10
Total debt			$	14,099	$	12,479
Less current maturities of debt			214		7
Total long-term debt			$	13,885	$	12,472
			March 2022		December 2021
Unamortized debt issuance costs			$	59	$	62
Borrowing capacity on existing facilities			$	2,162	$	2,162
Fair value of senior unsecured notes			$	12,369	$	13,391

The fair value of the senior unsecured notes was estimated using quoted interest rates, maturities and amounts of borrowings based on quoted active market prices and yields that took into account the underlying terms of the debt instruments. Substantially all of our debt is classified within Level 2 of the fair value hierarchy.

XML

Income Taxes

3 Months Ended

Mar. 31, 2022

Income Tax [Abstract]

Income Taxes

INCOME TAXES

Our effective tax rates were 16.3% and 17.7% in the three months 2022 and 2021. The change in the effective income tax rate for the three months was primarily due to lower tax expense from our operating structure and current profit mix.

We are routinely audited by income tax authorities in the jurisdictions we operate. It is reasonably possible within the next 12 months that uncertain tax positions, excluding interest, could decrease by as much as $175 as a result of the resolution of tax matters.

XML

Segment Information

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Segment Information

SEGMENT INFORMATION

As previously disclosed, effective December 31, 2021 we changed our reportable business segments to (i) MedSurg and Neurotechnology and (ii) Orthopaedics and Spine to align to our new internal reporting structure.

	Three Months
	2022		2021
MedSurg and Neurotechnology	$	2,423	$	2,191
Orthopaedics and Spine	1,852		1,762
Net sales	$	4,275	$	3,953
MedSurg and Neurotechnology	$	611	$	635
Orthopaedics and Spine	522		455
Segment operating income	$	1,133	$	1,090
Items not allocated to segments:
Corporate and other	$	(199)	$	(162)
Acquisition and integration-related costs	(149)		(249)
Amortization of intangible assets	(150)		(181)
Restructuring-related and other charges	(109)		(14)
Medical device regulations	(28)		(19)
Recall-related matters	(14)		(6)
Regulatory and legal matters	(37)		—
Consolidated operating income	$	447	$	459

There were no significant changes to total assets by segment from information provided in our Annual Report on Form 10-K for 2021, other than the addition of the assets acquired in the Vocera acquisition which are included in the MedSurg and Neurotechnology segment.

XML

Basis Of Presentation (Policies)

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

New Accounting Pronouncements

New Accounting Pronouncements Not Yet Adopted

We evaluate all Accounting Standards Updates (ASUs) issued by the Financial Accounting Standards Board (FASB) for consideration of their applicability. ASUs not included in our disclosures were assessed and determined to be either not applicable or are not expected to have a material impact on our Consolidated Financial Statements.

New Accounting Pronouncements Recently Adopted

On January 1, 2022 we adopted ASU 2021-08, Business Combinations: Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. This update requires an entity to recognize and measure contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standards Codification 606, Revenue from Contracts with Customers. The adoption of this update did not have a material impact on our Consolidated Financial Statements.

XML

Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2022

Revenue Recognition [Abstract]

Schedule of Disaggregated Revenue

We disaggregate our net sales by product line and geographic location for each of our segments as we believe it best depicts how the nature, amount, timing and certainty of our net sales and cash flows are affected by economic factors.

Net Sales by Product Line
	Three Months
	2022		2021
MedSurg and Neurotechnology:
Instruments	$	528	$	469
Endoscopy	538		469
Medical	664		622
Neurovascular	301		289
Neuro Cranial	323		281
Other	69		61
	$	2,423	$	2,191
Orthopaedics and Spine:
Knees	$	464	$	412
Hips	327		309
Trauma and Extremities	685		640
Spine	279		278
Other	97		123
	$	1,852	$	1,762
Total	$	4,275	$	3,953

Net Sales by Geography
	Three Months 2022				Three Months 2021
	United States		International		United States		International
MedSurg and Neurotechnology:
Instruments	$	414	$	114	$	355	$	114
Endoscopy	418		120		354		115
Medical	525		139		473		149
Neurovascular	110		191		111		178
Neuro Cranial	264		59		224		57
Other	68		1		60		1
	$	1,799	$	624	$	1,577	$	614
Orthopaedics and Spine:
Knees	$	345	$	119	$	294	$	118
Hips	202		125		186		123
Trauma and Extremities	487		198		440		200
Spine	200		79		193		85
Other	72		25		94		29
	$	1,306	$	546	$	1,207	$	555
Total	$	3,105	$	1,170	$	2,784	$	1,169

XML

Accumulated Other Comprehensive (Loss) Income (AOCI) (Tables)

3 Months Ended

Mar. 31, 2022

Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Three Months 2022	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	—	$	(155)	$	40	$	(416)	$	(531)
OCI	(1)		(4)		4		86		85
Income taxes	—		2		(2)		(25)		(25)
Reclassifications to:
Other (income) expense	—		2		(1)		(11)		(10)
Income taxes	—		(1)		—		3		2
Net OCI	$	(1)	$	(1)	$	1	$	53	$	52
Ending	$	(1)	$	(156)	$	41	$	(363)	$	(479)

Three Months 2021	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(259)	$	(10)	$	(885)	$	(1,157)
OCI	—		8		27		273		308
Income taxes	—		(4)		(8)		(12)		(24)
Reclassifications to:
Cost of sales	—		—		1		—		1
Other (income) expense	—		4		10		(8)		6
Income taxes	—		(1)		(2)		2		(1)
Net OCI	$	—	$	7	$	28	$	255	$	290
Ending	$	(3)	$	(252)	$	18	$	(630)	$	(867)

Reclassification out of Accumulated Other Comprehensive Income

Three Months 2022	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	—	$	(155)	$	40	$	(416)	$	(531)
OCI	(1)		(4)		4		86		85
Income taxes	—		2		(2)		(25)		(25)
Reclassifications to:
Other (income) expense	—		2		(1)		(11)		(10)
Income taxes	—		(1)		—		3		2
Net OCI	$	(1)	$	(1)	$	1	$	53	$	52
Ending	$	(1)	$	(156)	$	41	$	(363)	$	(479)

Three Months 2021	Marketable Securities		Pension Plans		Hedges		Financial Statement Translation		Total
Beginning	$	(3)	$	(259)	$	(10)	$	(885)	$	(1,157)
OCI	—		8		27		273		308
Income taxes	—		(4)		(8)		(12)		(24)
Reclassifications to:
Cost of sales	—		—		1		—		1
Other (income) expense	—		4		10		(8)		6
Income taxes	—		(1)		(2)		2		(1)
Net OCI	$	—	$	7	$	28	$	255	$	290
Ending	$	(3)	$	(252)	$	18	$	(630)	$	(867)

XML

Derivative Instruments (Tables)

3 Months Ended

Mar. 31, 2022

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Schedule of Derivative Instruments in Statement of Financial Position, Fair Value

March 2022	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	711	$	2,224	$	3,993	$	6,928
Maximum term in years							4.6
Fair value:
Other current assets	$	16	$	49	$	33	$	98
Other noncurrent assets	1		74		—		75
Other current liabilities	(7)		—		(29)		(36)
Other noncurrent liabilities	(1)		—		—		(1)
Total fair value	$	9	$	123	$	4	$	136

December 2021	Cash Flow		Net Investment		Non-Designated		Total
Gross notional amount	$	973	$	2,266	$	5,512	$	8,751
Maximum term in years							4.9
Fair value:
Other current assets	$	15	$	39	$	92	$	146
Other noncurrent assets	1		65		—		66
Other current liabilities	(7)		—		(10)		(17)
Total fair value	$	9	$	104	$	82	$	195

Schedule of Derivatives Instruments Statements of Financial Performance and Financial Position, Location

Derivative		Three Months
instrument:	Recorded in:	2022		2021
Cash Flow	Cost of sales	$	—	$	(1)
Net Investment	Other income (expense), net	11		8
Non-Designated	Other income (expense), net	1		(2)
	Total	$	12	$	5

XML

Fair Value Measurements (Tables)

3 Months Ended

Mar. 31, 2022

Fair Value Disclosures [Abstract]

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

Assets Measured at Fair Value	March		December
	2022		2021
Cash and cash equivalents	$	1,458	$	2,944
Trading marketable securities	182		193
Level 1 - Assets	$	1,640	$	3,137
Available-for-sale marketable securities:
Corporate and asset-backed debt securities	$	49	$	48
Foreign government debt securities	2		2
United States agency debt securities	5		5
United States Treasury debt securities	14		19
Certificates of deposit	2		1
Total available-for-sale marketable securities	$	72	$	75
Foreign currency exchange forward contracts	173		212
Level 2 - Assets	$	245	$	287
Total assets measured at fair value	$	1,885	$	3,424

Liabilities Measured at Fair Value	March		December
	2022		2021
Deferred compensation arrangements	$	182	$	193
Level 1 - Liabilities	$	182	$	193
Foreign currency exchange forward contracts	$	37	$	17
Level 2 - Liabilities	$	37	$	17
Contingent consideration:
Beginning	$	306	$	393
Additions	—		62
Change in estimate	(17)		(1)
Settlements	(4)		(148)
Ending	$	285	$	306
Level 3 - Liabilities	$	285	$	306
Total liabilities measured at fair value	$	504	$	516

Investments Classified by Contractual Maturity Date

Fair Value of Available for Sale Securities by Maturity
	March 2022		December 2021
Due in one year or less	$	40	$	36
Due after one year through three years	$	32	$	39

XML

Contingencies and Commitments (Tables)

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

Lease, Cost

Leases	March			December
	2022			2021
Right-of-use assets	$	490		$	419
Lease liabilities, current	$	129		$	112
Lease liabilities, non-current	$	370		$	310
Other information:
Weighted-average remaining lease term	5.5 years			5.4 years
Weighted-average discount rate	2.65		%	2.86		%

	Three Months
	2022		2021
Operating lease cost	$	31	$	36

XML

Acquisitions (Tables)

3 Months Ended

Mar. 31, 2022

Business Combinations [Abstract]

Schedule of Business Acquisitions, by Acquisition

Purchase price allocations for our significant acquisitions are:

Purchase Price Allocation of Acquired Net Assets
2022	Vocera
Tangible assets and liabilities:
Accounts receivable	$	33
Inventory	13
Deferred income tax assets	70
Other assets	92
Debt	(425)
Deferred income tax liabilities	(183)
Other liabilities	(115)
Intangible assets:
Customer and distributor relationships	550
Developed technology and patents	178
Trade name	18
Goodwill	2,332
Purchase price, net of cash acquired of $281	$	2,563
Weighted-average life of intangible assets	13

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense

Consolidated Estimated Amortization Expense
Remainder of 2022		2023		2024		2025		2026
$	484	$	624	$	594	$	573	$	515

XML

Debt and Credit Facilities (Tables)

3 Months Ended

Mar. 31, 2022

Long-term Debt, Unclassified [Abstract]

Schedule of Long-term Debt Instruments

Summary of Total Debt			March 2022		December 2021
	Rate	Due
Senior unsecured notes:
	1.125%	November 30, 2023	$	610	$	622
	0.600%	December 1, 2023	594		598
	3.375%	May 15, 2024	598		593
	0.250%	December 3, 2024	941		958
	1.150%	June 15, 2025	646		645
	3.375%	November 1, 2025	748		748
	3.500%	March 15, 2026	994		994
	2.125%	November 30, 2027	829		845
	3.650%	March 7, 2028	597		597
	0.750%	March 1, 2029	885		901
	1.950%	June 15, 2030	990		990
	2.625%	November 30, 2030	714		727
	1.000%	December 3, 2031	824		840
	4.100%	April 1, 2043	392		392
	4.375%	May 15, 2044	395		395
	4.625%	March 15, 2046	982		982
	2.900%	June 15, 2050	642		642
Term loan		February 22, 2025	1,500		—
Commercial paper			195		—
Other			23		10
Total debt			$	14,099	$	12,479
Less current maturities of debt			214		7
Total long-term debt			$	13,885	$	12,472
			March 2022		December 2021
Unamortized debt issuance costs			$	59	$	62
Borrowing capacity on existing facilities			$	2,162	$	2,162
Fair value of senior unsecured notes			$	12,369	$	13,391

XML

Segment Information (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Sales and Other Financial Information by Business Segment

	Three Months
	2022		2021
MedSurg and Neurotechnology	$	2,423	$	2,191
Orthopaedics and Spine	1,852		1,762
Net sales	$	4,275	$	3,953
MedSurg and Neurotechnology	$	611	$	635
Orthopaedics and Spine	522		455
Segment operating income	$	1,133	$	1,090
Items not allocated to segments:
Corporate and other	$	(199)	$	(162)
Acquisition and integration-related costs	(149)		(249)
Amortization of intangible assets	(150)		(181)
Restructuring-related and other charges	(109)		(14)
Medical device regulations	(28)		(19)
Recall-related matters	(14)		(6)
Regulatory and legal matters	(37)		—
Consolidated operating income	$	447	$	459

XML

Revenue Recognition - Disaggregated Sales Analysis (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 4,275	$ 3,953
United States
Disaggregation of Revenue [Line Items]
Net sales	3,105	2,784
International
Disaggregation of Revenue [Line Items]
Net sales	1,170	1,169
MedSurg and Neurotechnology:
Disaggregation of Revenue [Line Items]
Net sales	2,423	2,191
MedSurg and Neurotechnology: | United States
Disaggregation of Revenue [Line Items]
Net sales	1,799	1,577
MedSurg and Neurotechnology: | International
Disaggregation of Revenue [Line Items]
Net sales	624	614
MedSurg and Neurotechnology: | Instruments
Disaggregation of Revenue [Line Items]
Net sales	528	469
MedSurg and Neurotechnology: | Instruments | United States
Disaggregation of Revenue [Line Items]
Net sales	414	355
MedSurg and Neurotechnology: | Instruments | International
Disaggregation of Revenue [Line Items]
Net sales	114	114
MedSurg and Neurotechnology: | Endoscopy
Disaggregation of Revenue [Line Items]
Net sales	538	469
MedSurg and Neurotechnology: | Endoscopy | United States
Disaggregation of Revenue [Line Items]
Net sales	418	354
MedSurg and Neurotechnology: | Endoscopy | International
Disaggregation of Revenue [Line Items]
Net sales	120	115
MedSurg and Neurotechnology: | Medical
Disaggregation of Revenue [Line Items]
Net sales	664	622
MedSurg and Neurotechnology: | Medical | United States
Disaggregation of Revenue [Line Items]
Net sales	525	473
MedSurg and Neurotechnology: | Medical | International
Disaggregation of Revenue [Line Items]
Net sales	139	149
MedSurg and Neurotechnology: | Neurovascular
Disaggregation of Revenue [Line Items]
Net sales	301	289
MedSurg and Neurotechnology: | Neurovascular | United States
Disaggregation of Revenue [Line Items]
Net sales	110	111
MedSurg and Neurotechnology: | Neurovascular | International
Disaggregation of Revenue [Line Items]
Net sales	191	178
MedSurg and Neurotechnology: | Neuro Cranial
Disaggregation of Revenue [Line Items]
Net sales	323	281
MedSurg and Neurotechnology: | Neuro Cranial | United States
Disaggregation of Revenue [Line Items]
Net sales	264	224
MedSurg and Neurotechnology: | Neuro Cranial | International
Disaggregation of Revenue [Line Items]
Net sales	59	57
MedSurg and Neurotechnology: | Other
Disaggregation of Revenue [Line Items]
Net sales	69	61
MedSurg and Neurotechnology: | Other | United States
Disaggregation of Revenue [Line Items]
Net sales	68	60
MedSurg and Neurotechnology: | Other | International
Disaggregation of Revenue [Line Items]
Net sales	1	1
Orthopaedics and Spine:
Disaggregation of Revenue [Line Items]
Net sales	1,852	1,762
Orthopaedics and Spine: | United States
Disaggregation of Revenue [Line Items]
Net sales	1,306	1,207
Orthopaedics and Spine: | International
Disaggregation of Revenue [Line Items]
Net sales	546	555
Orthopaedics and Spine: | Other
Disaggregation of Revenue [Line Items]
Net sales	97	123
Orthopaedics and Spine: | Other | United States
Disaggregation of Revenue [Line Items]
Net sales	72	94
Orthopaedics and Spine: | Other | International
Disaggregation of Revenue [Line Items]
Net sales	25	29
Orthopaedics and Spine: | Knees
Disaggregation of Revenue [Line Items]
Net sales	464	412
Orthopaedics and Spine: | Knees | United States
Disaggregation of Revenue [Line Items]
Net sales	345	294
Orthopaedics and Spine: | Knees | International
Disaggregation of Revenue [Line Items]
Net sales	119	118
Orthopaedics and Spine: | Hips
Disaggregation of Revenue [Line Items]
Net sales	327	309
Orthopaedics and Spine: | Hips | United States
Disaggregation of Revenue [Line Items]
Net sales	202	186
Orthopaedics and Spine: | Hips | International
Disaggregation of Revenue [Line Items]
Net sales	125	123
Orthopaedics and Spine: | Trauma and Extremities
Disaggregation of Revenue [Line Items]
Net sales	685	640
Orthopaedics and Spine: | Trauma and Extremities | United States
Disaggregation of Revenue [Line Items]
Net sales	487	440
Orthopaedics and Spine: | Trauma and Extremities | International
Disaggregation of Revenue [Line Items]
Net sales	198	200
Orthopaedics and Spine: | Spine
Disaggregation of Revenue [Line Items]
Net sales	279	278
Orthopaedics and Spine: | Spine | United States
Disaggregation of Revenue [Line Items]
Net sales	200	193
Orthopaedics and Spine: | Spine | International
Disaggregation of Revenue [Line Items]
Net sales	$ 79	$ 85

XML

Revenue Recognition - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Revenue Recognition [Abstract]
Contract liabilities	$ 635	$ 529

XML

Accumulated Other Comprehensive (Loss) Income (AOCI) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	$ (531)	$ (1,157)
OCI	85	308
Income taxes	(25)	(24)
Cost of sales	1,541	1,444
Other (income) expense	(61)	(92)
Income taxes	(63)	(65)
Net OCI	52	290
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(479)	(867)
Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales		1
Other (income) expense	(10)	6
Income taxes	2	(1)
Net OCI	52	290
Marketable Securities
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	0	(3)
OCI	(1)	0
Income taxes	0	0
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(1)	(3)
Marketable Securities | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales		0
Other (income) expense	0	0
Income taxes	0	0
Net OCI	(1)	0
Pension Plans
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(155)	(259)
OCI	(4)	8
Income taxes	2	(4)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(156)	(252)
Pension Plans | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales		0
Other (income) expense	2	4
Income taxes	(1)	(1)
Net OCI	(1)	7
Hedges
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	40	(10)
OCI	4	27
Income taxes	(2)	(8)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	41	18
Hedges | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales		1
Other (income) expense	(1)	10
Income taxes	0	(2)
Net OCI	1	28
Financial Statement Translation
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Accumulated Other Comprehensive Income (Loss), Net of Tax at beginning of period	(416)	(885)
OCI	86	273
Income taxes	(25)	(12)
Accumulated Other Comprehensive Income (Loss), Net of Tax at end of period	(363)	(630)
Financial Statement Translation | Reclassification out of Accumulated Other Comprehensive Income
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Cost of sales		0
Other (income) expense	(11)	(8)
Income taxes	3	2
Net OCI	$ 53	$ 255

XML

Derivative Instruments (Forward Currency Exchange Contracts) (Details) - Foreign Exchange Contract € in Millions, $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2022 EUR (€)	Dec. 31, 2021 EUR (€)
Derivative [Line Items]
Notional Amount	$ 6,928	$ 8,751
Maximum term in years	4 years 7 months 6 days	4 years 10 months 24 days
Derivative, Fair Value, Net	$ 136	$ 195
Other current assets
Derivative [Line Items]
Derivative assets	98	146
Other noncurrent assets
Derivative [Line Items]
Derivative assets	75	66
Other current liabilities
Derivative [Line Items]
Derivative liabilities	(36)	(17)
Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities	(1)
Net Investment
Derivative [Line Items]
Notional Amount | €			€ 4,400	€ 4,400
Non-Designated
Derivative [Line Items]
Notional Amount	3,993	5,512
Derivative, Fair Value, Net	4	82
Non-Designated | Other current assets
Derivative [Line Items]
Derivative assets	33	92
Non-Designated | Other noncurrent assets
Derivative [Line Items]
Derivative assets	0	0
Non-Designated | Other current liabilities
Derivative [Line Items]
Derivative liabilities	(29)	(10)
Non-Designated | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities	0
Cash Flow | Net Investment
Derivative [Line Items]
Notional Amount	711	973
Derivative, Fair Value, Net	9	9
Cash Flow | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets	16	15
Cash Flow | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets	1	1
Cash Flow | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities	(7)	(7)
Cash Flow | Net Investment | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities	(1)
Net Investment | Net Investment
Derivative [Line Items]
Notional Amount	2,224	2,266
Derivative, Fair Value, Net	123	104
Net Investment | Net Investment | Other current assets
Derivative [Line Items]
Derivative assets	49	39
Net Investment | Net Investment | Other noncurrent assets
Derivative [Line Items]
Derivative assets	74	65
Net Investment | Net Investment | Other current liabilities
Derivative [Line Items]
Derivative liabilities	0	$ 0
Net Investment | Net Investment | Other noncurrent liabilities
Derivative [Line Items]
Derivative liabilities	$ 0

XML

Derivative Instruments (Narrative) (Details) $ in Millions	3 Months Ended
	Mar. 31, 2022 USD ($)	Mar. 31, 2022 EUR (€)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 EUR (€)
Foreign Exchange Contract
Notional amount	$ 6,928		$ 8,751
Designated as Hedging Instrument | Foreign Exchange Contract
Derivative, notional amount | €		€ 2,000,000,000		€ 2,000,000,000
Notional amount | €		€ 4,400,000,000		€ 4,400,000,000
Derivative, fair value	42
Cash flow hedge gain (loss) to be reclassified within twelve months	13
Net investment hedges expected to be reclassified to cost of sales and other income (expense)	34
Designated as Hedging Instrument | Interest Rate Swap
Cash flow hedge gain (loss) to be reclassified within twelve months	$ 5

XML

Derivative Instruments (Income Statement Location) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Foreign Exchange Contract
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 12	$ 5
Foreign Exchange Contract | Cost of sales
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	0	(1)
Foreign Exchange Contract | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	1	(2)
Net Investment | Other income (expense), net
Derivative Instruments, Gain (Loss) [Line Items]
Net currency exchange rate gains (losses)	$ 11	$ 8

XML

Fair Value Measurements (Valuation Of Financial Instruments By Pricing Categories) (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 1,458	$ 2,944
Assets
Available-for-sale securities, current	72	75
Investments Fair Value Disclosure	1,885	3,424
Contingent consideration:
Total liabilities measured at fair value	504	516
Fair Value, Inputs, Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	1,458	2,944
Trading marketable securities	182	193
Assets
Investments Fair Value Disclosure	1,640	3,137
Deferred compensation arrangements	182	193
Contingent consideration:
Total liabilities measured at fair value	182	193
Fair Value, Inputs, Level 2
Assets
Available-for-sale securities, current	72	75
Investments Fair Value Disclosure	245	287
Contingent consideration:
Total liabilities measured at fair value	37	17
Fair Value, Inputs, Level 2 | Foreign currency exchange forward contracts
Assets
Derivative asset	173	212
Liabilities
Foreign currency exchange forward contracts	37	17
Fair Value, Inputs, Level 2 | Corporate and asset-backed debt securities
Assets
Available-for-sale securities, current	49	48
Fair Value, Inputs, Level 2 | Foreign government
Assets
Available-for-sale securities, current	2	2
Fair Value, Inputs, Level 2 | United States agency debt securities
Assets
Available-for-sale securities, current	5	5
Fair Value, Inputs, Level 2 | United States Treasury debt securities
Assets
Available-for-sale securities, current	14	19
Fair Value, Inputs, Level 2 | Certificates of deposit
Assets
Available-for-sale securities, current	2	1
Fair Value, Inputs, Level 3
Contingent consideration:
Beginning	306	393
Additions	0	62
Change in estimate	(17)	(1)
Settlements	(4)	(148)
Ending	285	306
Total liabilities measured at fair value	$ 285	$ 306

XML

Fair Value Measurements (Assets and Liabilities Measured At Fair Value On A Recurring Basis Using Unobservable Inputs (Level 3)) (Details) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Due in one year or less	$ 40	$ 36
Due after one year through three years	$ 32	$ 39

XML

Fair Value Measurements (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Fair Value Disclosures [Abstract]
Gain on sale of marketable securities	$ 15	$ 17

XML

Contingencies and Commitments (Narrative) (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021
Loss Contingencies [Line Items]
Recall-related payments		$ (9)	$ (8)
Settled Litigation
Loss Contingencies [Line Items]
Charges during period		14
PureWick
Loss Contingencies [Line Items]
Charges during period	$ 28
Estimate of possible loss	100	100
Minimum
Loss Contingencies [Line Items]
Estimate of possible loss	385	385
Maximum
Loss Contingencies [Line Items]
Estimate of possible loss	$ 520	$ 520

XML

Contingencies and Commitments - Leases (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets	$ 490		$ 419
Lease liabilities, current	129		112
Lease liabilities, non-current	$ 370		$ 310
Other information:
Weighted-average remaining lease term	5 years 6 months		5 years 4 months 24 days
Weighted-average discount rate	2.65%		2.86%
Operating lease cost	$ 31	$ 36

XML

Acquisitions (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Feb. 28, 2022	Mar. 31, 2022	Mar. 31, 2021
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions		$ 2,563	$ 31
Payments of long-term debt		0	$ 750
Vocera
Business Acquisition [Line Items]
Aggregate purchase price of acquisitions	$ 2,600
Consideration transferred (in dollars per share)	$ 79.25
Business combination, consideration transferred, including convertible notes	$ 3,000
Share-based payment expense		$ 132
Vocera | 1.50% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate		1.50%
Payments of long-term debt		$ 101
Vocera | 0.50% Convertible Notes
Business Acquisition [Line Items]
Stated interest rate		0.50%
Payments of long-term debt		$ 324

XML

Acquisitions (Allocation Of The Preliminary Purchase Price To The Acquired Net Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Goodwill	$ 15,228	$ 12,918
Vocera
Accounts receivable	33
Inventory	13
Deferred income tax assets	70
Other assets	92
Debt	(425)
Deferred income tax liabilities	(183)
Other liabilities	(115)
Goodwill	2,332
Purchase price, net of cash acquired of $281	$ 2,563
Weighted-average life of intangible assets	13 years
Vocera | Customer and distributor relationships
Intangible assets acquired	$ 550
Vocera | Developed technology and patents
Intangible assets acquired	178
Vocera | Trade name
Intangible assets acquired	$ 18

XML

Acquisitions (Future Amortization Expense) (Details) $ in Millions	Mar. 31, 2022 USD ($)
Business Combinations [Abstract]
Remainder of 2022	$ 484
2023	624
2024	594
2025	573
2026	$ 515

XML

Debt and Credit Facilities (Details) - USD ($)	1 Months Ended	3 Months Ended
	Feb. 28, 2022	Mar. 31, 2022	Dec. 31, 2021
Commercial paper		$ 195,000,000	$ 0
Other Long-term Debt		23,000,000	10,000,000
Total debt		14,099,000,000	12,479,000,000
Less current maturities of debt		214,000,000	7,000,000
Total long-term debt		13,885,000,000	12,472,000,000
Unamortized debt issuance costs		59,000,000	62,000,000
Borrowing capacity on existing facilities		2,162,000,000	2,162,000,000
Fair value of senior unsecured notes		$ 12,369,000,000	13,391,000,000
Term Loan
Debt instrument, face amount	$ 1,500,000,000
Basis spread on variable rate (as a percent)	0.725%
Maturity Date		Feb. 22, 2025
Long-term Debt		$ 1,500,000,000	0
Credit Agreement | Revolving Credit Facility
Line of credit facility, maximum borrowing capacity		$ 2,250,000,000	1,500,000,000
Senior Unsecured Notes 1.125% due 2021
Stated interest rate		1.125%
Maturity Date		Nov. 30, 2023
Unsecured Debt		$ 610,000,000	622,000,000
Senior Unsecured Notes, 0.600% Due 2023
Stated interest rate		0.60%
Maturity Date		Dec. 01, 2023
Unsecured Debt		$ 594,000,000	598,000,000
Senior Unsecured Notes 3.375% due 2024
Stated interest rate		3.375%
Maturity Date		May 15, 2024
Unsecured Debt		$ 598,000,000	593,000,000
Senior Unsecured Notes, 0.250% Due 2024
Stated interest rate		0.25%
Maturity Date		Dec. 03, 2024
Unsecured Debt		$ 941,000,000	958,000,000
Senior Unsecured Notes, 1.150% Due 2025
Stated interest rate		1.15%
Maturity Date		Jun. 15, 2025
Unsecured Debt		$ 646,000,000	645,000,000
Senior Unsecured Notes 3.375% due 2025
Stated interest rate		3.375%
Maturity Date		Nov. 01, 2025
Unsecured Debt		$ 748,000,000	748,000,000
Senior Unsecured Notes 3.50% due 2026
Stated interest rate		3.50%
Maturity Date		Mar. 15, 2026
Unsecured Debt		$ 994,000,000	994,000,000
Senior Unsecured Notes 2.125% due 2027
Stated interest rate		2.125%
Maturity Date		Nov. 30, 2027
Unsecured Debt		$ 829,000,000	845,000,000
Senior Unsecured Notes 3.650% due 2028
Stated interest rate		3.65%
Maturity Date		Mar. 07, 2028
Unsecured Debt		$ 597,000,000	597,000,000
Senior Unsecured Notes, 0.750% Due 2029
Stated interest rate		0.75%
Maturity Date		Mar. 01, 2029
Unsecured Debt		$ 885,000,000	901,000,000
Senior Unsecured Notes, 1.950% Due 2030
Stated interest rate		1.95%
Maturity Date		Jun. 15, 2030
Unsecured Debt		$ 990,000,000	990,000,000
Senior Unsecured Notes 2.625% due 2030
Stated interest rate		2.625%
Maturity Date		Nov. 30, 2030
Unsecured Debt		$ 714,000,000	727,000,000
Senior Unsecured Notes, 1.000% Due 2031
Stated interest rate		1.00%
Maturity Date		Dec. 03, 2031
Unsecured Debt		$ 824,000,000	840,000,000
Senior Unsecured Notes 4.100% due 2043
Stated interest rate		4.10%
Maturity Date		Apr. 01, 2043
Unsecured Debt		$ 392,000,000	392,000,000
Senior Unsecured Notes 4.375% due 2044
Stated interest rate		4.375%
Maturity Date		May 15, 2044
Unsecured Debt		$ 395,000,000	395,000,000
Senior Unsecured Notes 4.625% due 2046
Stated interest rate		4.625%
Maturity Date		Mar. 15, 2046
Unsecured Debt		$ 982,000,000	982,000,000
Senior Unsecured Notes, 2.900% due 2050
Stated interest rate		2.90%
Maturity Date		Jun. 15, 2050
Unsecured Debt		$ 642,000,000	$ 642,000,000
Commercial Paper
Debt instrument, maturity		397 days

XML

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Income Tax [Abstract]
Effective income tax rate reconciliation, percent	16.30%	17.70%
Decrease in unrecognized tax positions is reasonably possible	$ 175

XML

Segment Information (Sales And Other Financial Information By Business Segment) (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 4,275	$ 3,953
Segment operating income	447	459
Amortization of intangible assets	(150)	(181)
Recall-related matters	(14)	(6)
MedSurg and Neurotechnology:
Segment Reporting Information [Line Items]
Net sales	2,423	2,191
Orthopaedics and Spine:
Segment Reporting Information [Line Items]
Net sales	1,852	1,762
Operating Segments
Segment Reporting Information [Line Items]
Segment operating income	1,133	1,090
Operating Segments | MedSurg and Neurotechnology:
Segment Reporting Information [Line Items]
Net sales	2,423	2,191
Segment operating income	611	635
Operating Segments | Orthopaedics and Spine:
Segment Reporting Information [Line Items]
Net sales	1,852	1,762
Segment operating income	522	455
Corporate and other
Segment Reporting Information [Line Items]
Segment operating income	(199)	(162)
Segment Reconciling Items
Segment Reporting Information [Line Items]
Acquisition and integration-related costs	(149)	(249)
Amortization of intangible assets	(150)	(181)
Restructuring-related and other charges	(109)	(14)
Medical device regulations	(28)	(19)
Recall-related matters	(14)	(6)
Regulatory and legal matters	$ (37)	$ 0